# EDGAR Filing Document

**Accession Number:** 0001568651
**File Stem:** 0001568651-26-000040
**Filing Date:** 2026-5
**Character Count:** 244435
**Document Hash:** c5e7ded2f968effae5ab6f6c6b8b846d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001568651-26-000040.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001568651-26-000040

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 106

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Oscar Health, Inc.
- **CENTRAL INDEX KEY:** 0001568651
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40154
- **FILM NUMBER:** 26953918

**BUSINESS ADDRESS:**
- **STREET 1:** 75 VARICK STREET
- **STREET 2:** 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013
- **BUSINESS PHONE:** (646) 403-3677

**MAIL ADDRESS:**
- **STREET 1:** 75 VARICK STREET
- **STREET 2:** 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mulberry Health Inc.
- **DATE OF NAME CHANGE:** 20130204

?xml version='1.0' encoding='ASCII'? oscr-20260331

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 10-Q** 

**[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026** 

**or** 

**[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from __________to__________**

**Commission File Number: 001-40154**

**____________________________________________________________**

**Oscar Health, Inc.**

(Exact name of registrant as specified in its charter)

**____________________________________________________________**

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **Delaware** | **46-1315570** |
| (State or other jurisdiction <br>of incorporation or organization) | (State or other jurisdiction <br>of incorporation or organization) | (State or other jurisdiction <br>of incorporation or organization) | (I.R.S. Employer <br>Identification No.) |
| &nbsp;&nbsp;**75 Varick Street, 5th Floor,** | **New York,** | **NY** | **10013** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(646) 403-3677** 

Former name, former address and former fiscal year, if changed since last report: **N/A**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Class A Common Stock, $0.00001 par value per share** | **OSCR** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

---

| | |
|:---|:---|
| **Class of Stock** | **Shares Outstanding as of April 30, 2026 (in thousands)** |
| Class A Common Stock, par value $0.00001 per share | 265902 |
| Class B Common Stock, par value $0.00001 per share | 35591 |

---

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Oscar Health, Inc.**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **<u>Page</u>** |
| **<u>[FORWARD LOOKING STATEMENTS](#ic0ed02a1d98540d0b02bc707fdf6e276_13)</u>** | **<u>[FORWARD LOOKING STATEMENTS](#ic0ed02a1d98540d0b02bc707fdf6e276_13)</u>** | <u>[3](#ic0ed02a1d98540d0b02bc707fdf6e276_13)</u> |
| **PART I - FINANCIAL INFORMATION** | **PART I - FINANCIAL INFORMATION** |  |
| Item 1. | **Financial Statements (unaudited)** |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Operations](#ic0ed02a1d98540d0b02bc707fdf6e276_22)</u>  | <u>[5](#ic0ed02a1d98540d0b02bc707fdf6e276_22)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive Income](#ic0ed02a1d98540d0b02bc707fdf6e276_25)</u> | <u>[6](#ic0ed02a1d98540d0b02bc707fdf6e276_25)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets](#ic0ed02a1d98540d0b02bc707fdf6e276_28)</u> | <u>[7](#ic0ed02a1d98540d0b02bc707fdf6e276_28)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Stockholders' Equity](#ic0ed02a1d98540d0b02bc707fdf6e276_31)</u> | <u>[8](#ic0ed02a1d98540d0b02bc707fdf6e276_31)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows](#ic0ed02a1d98540d0b02bc707fdf6e276_34)</u>  | <u>[9](#ic0ed02a1d98540d0b02bc707fdf6e276_34)</u> |
|  | **<u>[Notes to Condensed Consolidated Financial Statements](#ic0ed02a1d98540d0b02bc707fdf6e276_37)</u>** |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 1 - Organization](#ic0ed02a1d98540d0b02bc707fdf6e276_40)</u> | <u>[10](#ic0ed02a1d98540d0b02bc707fdf6e276_40)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 2 - Earnings Per Share](#ic0ed02a1d98540d0b02bc707fdf6e276_43)</u> | <u>[12](#ic0ed02a1d98540d0b02bc707fdf6e276_43)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 3 - Revenue Recognition](#ic0ed02a1d98540d0b02bc707fdf6e276_46)</u> | <u>[13](#ic0ed02a1d98540d0b02bc707fdf6e276_46)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note](#ic0ed02a1d98540d0b02bc707fdf6e276_49)[4](#ic0ed02a1d98540d0b02bc707fdf6e276_49)[- Investments](#ic0ed02a1d98540d0b02bc707fdf6e276_49)</u> | <u>[13](#ic0ed02a1d98540d0b02bc707fdf6e276_49)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note](#ic0ed02a1d98540d0b02bc707fdf6e276_52)[5](#ic0ed02a1d98540d0b02bc707fdf6e276_52)[- Fair Value Measurements](#ic0ed02a1d98540d0b02bc707fdf6e276_52)</u>  | <u>[15](#ic0ed02a1d98540d0b02bc707fdf6e276_52)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note](#ic0ed02a1d98540d0b02bc707fdf6e276_55)[6](#ic0ed02a1d98540d0b02bc707fdf6e276_55)[- Restricted Cash and Restricted Deposits](#ic0ed02a1d98540d0b02bc707fdf6e276_55)</u> | <u>[16](#ic0ed02a1d98540d0b02bc707fdf6e276_55)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note](#ic0ed02a1d98540d0b02bc707fdf6e276_58)[7](#ic0ed02a1d98540d0b02bc707fdf6e276_58)[- Benefits Payable](#ic0ed02a1d98540d0b02bc707fdf6e276_58)</u> | <u>[17](#ic0ed02a1d98540d0b02bc707fdf6e276_58)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note](#ic0ed02a1d98540d0b02bc707fdf6e276_82)[8](#ic0ed02a1d98540d0b02bc707fdf6e276_82)[- Risk Adjustment](#ic0ed02a1d98540d0b02bc707fdf6e276_82)</u> | <u>[18](#ic0ed02a1d98540d0b02bc707fdf6e276_82)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note](#ic0ed02a1d98540d0b02bc707fdf6e276_61)[9](#ic0ed02a1d98540d0b02bc707fdf6e276_61)[- Debt](#ic0ed02a1d98540d0b02bc707fdf6e276_61)</u> | <u>[19](#ic0ed02a1d98540d0b02bc707fdf6e276_61)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note](#ic0ed02a1d98540d0b02bc707fdf6e276_67)[1](#ic0ed02a1d98540d0b02bc707fdf6e276_67)[0](#ic0ed02a1d98540d0b02bc707fdf6e276_67)[- Reinsurance](#ic0ed02a1d98540d0b02bc707fdf6e276_67)</u> | <u>[21](#ic0ed02a1d98540d0b02bc707fdf6e276_67)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 1](#ic0ed02a1d98540d0b02bc707fdf6e276_73)[1](#ic0ed02a1d98540d0b02bc707fdf6e276_73)[- Related Party Transactions](#ic0ed02a1d98540d0b02bc707fdf6e276_73)</u>  | <u>[22](#ic0ed02a1d98540d0b02bc707fdf6e276_73)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 1](#ic0ed02a1d98540d0b02bc707fdf6e276_76)[2](#ic0ed02a1d98540d0b02bc707fdf6e276_76)[- Commitments and Contingencies](#ic0ed02a1d98540d0b02bc707fdf6e276_76)</u> | <u>[22](#ic0ed02a1d98540d0b02bc707fdf6e276_76)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note](#ic0ed02a1d98540d0b02bc707fdf6e276_79)[13](#ic0ed02a1d98540d0b02bc707fdf6e276_79)[- Segment Information](#ic0ed02a1d98540d0b02bc707fdf6e276_79)</u> | <u>[24](#ic0ed02a1d98540d0b02bc707fdf6e276_79)</u> |
| Item 2. | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#ic0ed02a1d98540d0b02bc707fdf6e276_85)</u> | <u>[25](#ic0ed02a1d98540d0b02bc707fdf6e276_85)</u> |
| Item 3. | <u>[Quantitative and Qualitative Disclosures about Market Risk](#ic0ed02a1d98540d0b02bc707fdf6e276_112)</u> | <u>[37](#ic0ed02a1d98540d0b02bc707fdf6e276_112)</u> |
| Item 4. | <u>[Controls and Procedures](#ic0ed02a1d98540d0b02bc707fdf6e276_115)</u> | <u>[37](#ic0ed02a1d98540d0b02bc707fdf6e276_115)</u> |
| **PART II - OTHER INFORMATION** | **PART II - OTHER INFORMATION** |  |
| Item 1. | <u>[Legal Proceedings](#ic0ed02a1d98540d0b02bc707fdf6e276_121)</u> | <u>[38](#ic0ed02a1d98540d0b02bc707fdf6e276_121)</u> |
| Item 1A. | <u>[Risk Factors](#ic0ed02a1d98540d0b02bc707fdf6e276_124)</u> | <u>[38](#ic0ed02a1d98540d0b02bc707fdf6e276_124)</u> |
| Item 2. | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#ic0ed02a1d98540d0b02bc707fdf6e276_127)</u> | <u>[38](#ic0ed02a1d98540d0b02bc707fdf6e276_127)</u> |
| Item 3. | <u>[Defaults Upon Senior Securities](#ic0ed02a1d98540d0b02bc707fdf6e276_130)</u> | <u>[38](#ic0ed02a1d98540d0b02bc707fdf6e276_130)</u> |
| Item 4. | <u>[Mine Safety Disclosures](#ic0ed02a1d98540d0b02bc707fdf6e276_133)</u> | <u>[38](#ic0ed02a1d98540d0b02bc707fdf6e276_133)</u> |
| Item 5. | <u>[Other Information](#ic0ed02a1d98540d0b02bc707fdf6e276_136)</u> | <u>[38](#ic0ed02a1d98540d0b02bc707fdf6e276_136)</u> |
| Item 6. | <u>[Exhibits](#ic0ed02a1d98540d0b02bc707fdf6e276_142)</u> | <u>[40](#ic0ed02a1d98540d0b02bc707fdf6e276_142)</u> |
| <u>[SIGNATURES](#ic0ed02a1d98540d0b02bc707fdf6e276_145)</u> | <u>[SIGNATURES](#ic0ed02a1d98540d0b02bc707fdf6e276_145)</u> | <u>[41](#ic0ed02a1d98540d0b02bc707fdf6e276_145)</u> |

---

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

This Quarterly Report on Form 10-Q for the period ended March 31, 2026 ("Quarterly Report on Form 10-Q") contains the following defined terms, unless context otherwise requires: (i) "Oscar," "the Company," "we," "our," "us" or like terms refer to Oscar Health, Inc. and its subsidiaries, (ii) "Thrive Capital" refers to Thrive Capital Management, LLC, a Delaware limited liability company, and the investment funds affiliated with or advised by Thrive Capital Management, LLC and (iii) "Thrive General Partners" refers to Thrive Partners II GP, LLC, Thrive Partners III GP, LLC, Thrive Partners V GP, LLC, Thrive Partners VI GP, LLC, Thrive Partners VII GP, LLC, and Thrive Partners VII Growth GP, LLC, each of which is a general partner of a Thrive Capital-affiliated fund.

**FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "forecasts," "predicts," "potential" or "continues" or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements regarding our future results of operations and financial position, including risk adjustment transfer payments; industry, regulatory and business trends, including trends in medical expenses and overall market morbidity; our commercial arrangements, business strategy, plans and plan mix; membership and market growth; and our objectives for future operations.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to execute our strategy and manage our growth effectively (including our ability to successfully integrate strategic acquisitions);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to retain and expand our member base;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to accurately estimate our incurred medical expenses or overall market morbidity, or effectively manage our medical costs or related administrative costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Unanticipated results of, or changes to, risk adjustment programs or our estimates thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Evolving federal or state laws or regulations (including any changes in the interpretation or enforcement of existing laws and regulations), including changes with respect to the Patient Protection and Affordable Care Act ("ACA") and any regulations enacted thereunder, the expiration of the enhanced Advanced Premium Tax Credits ("eAPTCs"), the implementation of new program integrity rules, the potential funding of a cost-sharing reduction ("CSR") program, or other government actions, such as the imposition of tariffs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to achieve or maintain profitability in the future;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to arrange for the delivery of quality care and maintain good relations with brokers and the physicians, hospitals, and other providers within and outside our provider networks;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to comply with ongoing, complex and evolving regulatory requirements, including capital reserve and surplus requirements and applicable performance standards;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes or developments in the regulation of health insurance markets in the United States;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our, or any of our vendors', ability to comply with laws, regulations, and standards related to the handling of information about individuals or applicable consumer protection laws, including as a result of our participation in government-sponsored programs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The ability of our health insurance and Health Maintenance Organization ("HMO") subsidiaries (collectively, "Health Insurance Subsidiaries") to make payments of dividends or distributions to us, including to fund our business strategy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to utilize quota share reinsurance to meet our capital and surplus requirements and protect against downside risk on medical claims;

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adverse market conditions resulting in our investment portfolio suffering losses or reducing our ability to meet our financing needs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Unfavorable or otherwise costly outcomes of lawsuits, audits, investigations, and other third party claims that may arise from the extensive laws and regulations to which we are subject;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Incurrence of data security breaches of our or our partners' information and technology systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Heightened competition in the markets in which we participate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to attract and retain qualified personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Uncertainties associated with our utilization of certain artificial intelligence ("AI") and machine learning models;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to detect and prevent material weaknesses or significant control deficiencies in our internal controls over financial reporting or other failure to maintain an effective system of internal controls;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adverse publicity or other adverse consequences related to our dual class structure or "controlled company" status; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The other risks and uncertainties described under the caption "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on February 13, 2026.

The forward-looking statements in this Quarterly Report on Form 10-Q are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

This Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits to this Quarterly Report on Form 10-Q should be read with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this Quarterly Report on Form 10-Q, whether as a result of any new information, future events or otherwise.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**PART I. FINANCIAL INFORMATION**

 **Item 1. Financial Statements**

**Oscar Health, Inc.**

**Condensed Consolidated Statements of Operations**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands, except per share amounts) | **2026** | **2025** |
| **Revenue** |  |  |
| &nbsp;&nbsp;&nbsp;Premium | $4580862 | $2995821 |
| &nbsp;&nbsp;&nbsp;Investment income | 60614 | 46112 |
| &nbsp;&nbsp;&nbsp;Other revenues | 5718 | 4330 |
| Total revenue | 4647194 | 3046263 |
| **Operating Expenses** |  |  |
| &nbsp;&nbsp;&nbsp;Medical | 3229857 | 2259651 |
| &nbsp;&nbsp;&nbsp;Selling, general, and administrative | 706234 | 482759 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 7018 | 6730 |
| Total operating expenses | 3943109 | 2749140 |
| **Earnings from operations** | **704085** | **297123** |
| &nbsp;&nbsp;&nbsp;Interest expense | 5383 | 5994 |
| &nbsp;&nbsp;&nbsp;Other expenses (income) | (71) | 2918 |
| **Earnings before income taxes** | **698773** | **288211** |
| &nbsp;&nbsp;&nbsp;Income tax expense | 19750 | 12705 |
| **Net income** | **679023** | **275506** |
| &nbsp;&nbsp;&nbsp;Less: Net income attributable to noncontrolling interests | 27 | 235 |
| **Net income attributable to Oscar Health, Inc.** | $**678996** | $**275271** |
| **Earnings per Share** |  |  |
| Basic | $**2.28** | $**1.10** |
| Diluted | $**2.07** | $**0.92** |
| **Weighted Average Common Shares Outstanding** |  |  |
| Basic | **298184** | **251279** |
| Diluted | **329751** | **305938** |

---

See the accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Oscar Health, Inc.**

**Condensed Consolidated Statements of Comprehensive Income**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands) | **2026** | **2025** |
| **Net income** | $**679023** | $**275506** |
| Other comprehensive income (loss), net of tax: |  |  |
| &nbsp;&nbsp;Net unrealized gains (losses) on securities available for sale | (13030) | 11428 |
| **Comprehensive income** | **665993** | **286934** |
| Comprehensive income attributable to noncontrolling interests | 27 | 235 |
| **Comprehensive income attributable to Oscar Health, Inc.** | $**665966** | $**286699** |

---

See the accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Oscar Health, Inc.**

**Condensed Consolidated Balance Sheets**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| (in thousands, except per share amounts) | **March 31, 2026** | **December 31, 2025** |
| **Assets** |  |  |
| <u>Current Assets:</u> |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $4805139 | $2774151 |
| &nbsp;&nbsp;&nbsp;Short-term investments  | 1994644 | 1216461 |
| &nbsp;&nbsp;&nbsp;Accounts receivable (net of allowance for credit losses of $7,171 and $7,226) | 587023 | 362682 |
| &nbsp;&nbsp;&nbsp;Receivables from CMS | 222195 | 136029 |
| &nbsp;&nbsp;&nbsp;Reinsurance recoverable | 142487 | 99750 |
| &nbsp;&nbsp;&nbsp;Other current assets | 25817 | 24331 |
| Total current assets | 7777305 | 4613404 |
| &nbsp;&nbsp;&nbsp;Property, equipment, and capitalized software, net | 94194 | 88350 |
| &nbsp;&nbsp;&nbsp;Long-term investments | 1266775 | 1470987 |
| &nbsp;&nbsp;&nbsp;Restricted deposits | 28631 | 32951 |
| &nbsp;&nbsp;&nbsp;Other assets | 122741 | 119719 |
| **Total assets** | $**9289646** | $**6325411** |
| **Liabilities and Stockholders' Equity** |  |  |
| <u>Current Liabilities:</u> |  |  |
| &nbsp;&nbsp;&nbsp;Benefits payable | $1734051 | $1455385 |
| &nbsp;&nbsp;&nbsp;Payables to CMS | 4723244 | 2730095 |
| &nbsp;&nbsp;&nbsp;Accounts payable and other liabilities | 505943 | 507325 |
| &nbsp;&nbsp;&nbsp;Unearned premiums | 172004 | 166203 |
| &nbsp;&nbsp;&nbsp;Reinsurance payable | 5112 | 3579 |
| Total current liabilities | 7140354 | 4862587 |
| &nbsp;&nbsp;&nbsp;Long-term debt | 430876 | 430095 |
| &nbsp;&nbsp;&nbsp;Other liabilities | 51368 | 51994 |
| **Total liabilities** | **7622598** | **5344676** |
| Commitments and contingencies (Note 12) |  |  |
| **Stockholders' Equity** |  |  |
| &nbsp;&nbsp;&nbsp;Class A common stock ($0.00001 par value; 825,000 thousand shares authorized, 263,552 thousand and 261,851 thousand shares outstanding as of March 31, 2026 and December 31, 2025, respectively) | 3 | 3 |
| &nbsp;&nbsp;&nbsp;Class B common stock ($0.00001 par value; 82,500 thousand shares authorized, 35,591 thousand and 35,838 thousand shares outstanding as of March 31, 2026 and December 31, 2025, respectively) |  |  |
| &nbsp;&nbsp;&nbsp;Treasury stock (315 thousand shares as of March 31, 2026 and December 31, 2025) | (2923) | (2923) |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 4277292 | 4256972 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (2615438) | (3294434) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 5000 | 18030 |
| Total Oscar Health, Inc. stockholders' equity | 1663934 | 977648 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interests | 3114 | 3087 |
| Total stockholders' equity | 1667048 | 980735 |
| **Total liabilities and stockholders' equity** | $**9289646** | $**6325411** |

---

See the accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Oscar Health, Inc.**

**Condensed Consolidated Statements of Stockholders' Equity**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands) | **2026** | **2025** |
| **Common stock, Class A shares** |  |  |
| &nbsp;&nbsp;&nbsp;Balance, beginning of period | 261851 | 214974 |
| &nbsp;&nbsp;&nbsp;Issuance of common stock from equity incentive plans | 1454 | 3067 |
| &nbsp;&nbsp;&nbsp;Conversion of Class B shares to Class A shares | 247 |  |
| &nbsp;&nbsp;&nbsp;Shares withheld for net settlement of share-based awards |  | (58) |
| &nbsp;&nbsp;&nbsp;Balance, end of period | 263552 | 217983 |
| **Common stock, Class B shares** |  |  |
| &nbsp;&nbsp;&nbsp;Balance, beginning of period | 35838 | 35514 |
| &nbsp;&nbsp;&nbsp;Conversion of Class B shares to Class A shares | (247) |  |
| &nbsp;&nbsp;&nbsp;Balance, end of period | 35591 | 35514 |
| **Common stock, Class A** |  |  |
| &nbsp;&nbsp;&nbsp;Balance, beginning of period | $3 | $2 |
| &nbsp;&nbsp;&nbsp;Balance, end of period | 3 | 2 |
| **Common stock, Class B** |  |  |
| &nbsp;&nbsp;&nbsp;Balance, beginning of period |  |  |
| &nbsp;&nbsp;&nbsp;Balance, end of period |  |  |
| **Treasury stock** |  |  |
| &nbsp;&nbsp;&nbsp;Balance, beginning of period | (2923) | (2923) |
| &nbsp;&nbsp;&nbsp;Balance, end of period | (2923) | (2923) |
| **Additional paid-in capital** |  |  |
| &nbsp;&nbsp;&nbsp;Balance, beginning of period | 4256972 | 3869617 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 19181 | 27883 |
| &nbsp;&nbsp;&nbsp;Issuance of common stock from equity incentive plans | 1139 | 5728 |
| &nbsp;&nbsp;&nbsp;Net settlement for taxes related to share-based awards |  | (855) |
| &nbsp;&nbsp;&nbsp;Balance, end of period | 4277292 | 3902373 |
| **Accumulated deficit** |  |  |
| &nbsp;&nbsp;&nbsp;Balance, beginning of period | (3294434) | (2851283) |
| &nbsp;&nbsp;&nbsp;Net income attributable to Oscar Health, Inc. | 678996 | 275271 |
| &nbsp;&nbsp;&nbsp;Balance, end of period | (2615438) | (2576012) |
| **Accumulated other comprehensive income (loss)** |  |  |
| &nbsp;&nbsp;&nbsp;Balance, beginning of period | 18030 | (1827) |
| &nbsp;&nbsp;&nbsp;Unrealized gains (losses) on investments, net | (13030) | 11428 |
| &nbsp;&nbsp;&nbsp;Balance, end of period | 5000 | 9601 |
| **Noncontrolling interests** |  |  |
| &nbsp;&nbsp;&nbsp;Balance, beginning of period | 3087 | 2839 |
| &nbsp;&nbsp;&nbsp;Net income attributable to noncontrolling interests | 27 | 235 |
| &nbsp;&nbsp;&nbsp;Balance, end of period | 3114 | 3074 |
| **Total stockholders' equity** | $**1667048** | $**1336115** |

---

See the accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Oscar Health, Inc.**

**Condensed Consolidated Statements of Cash Flows**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands) | **2026** | **2025** |
| **Cash Flows from Operating Activities:** |  |  |
| **Net income** | $679023 | $275506 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;Deferred taxes | (6204) | 36 |
| &nbsp;&nbsp;Net realized gain on sale of financial instruments | (4) | (119) |
| &nbsp;&nbsp;Depreciation and amortization expense | 7018 | 6730 |
| &nbsp;&nbsp;&nbsp;Amortization of debt issuance costs | 1015 | 194 |
| &nbsp;&nbsp;Stock-based compensation expense | 15969 | 24975 |
| &nbsp;&nbsp;&nbsp;Net accretion of investments | (7077) | (7673) |
| &nbsp;&nbsp;&nbsp;Change in provision for credit losses | (55) | (8650) |
| Changes in assets and liabilities: |  |  |
| (Increase) / decrease in: |  |  |
| &nbsp;&nbsp;Receivables from CMS | (86165) | (88745) |
| &nbsp;&nbsp;&nbsp;Accounts receivable | (224288) | (97827) |
| &nbsp;&nbsp;Reinsurance recoverable | (42737) | 103990 |
| &nbsp;&nbsp;Other assets | 5344 | (13265) |
| Increase / (decrease) in: |  |  |
| &nbsp;&nbsp;Benefits payable | 278666 | 108848 |
| &nbsp;&nbsp;&nbsp;Payables to CMS | 1993149 | 571443 |
| &nbsp;&nbsp;Accounts payable and other liabilities | (2007) | 24294 |
| &nbsp;&nbsp;Unearned premiums | 5800 | (3492) |
| &nbsp;&nbsp;Reinsurance payable | 1533 | (17703) |
| **Net cash provided by operating activities** | **2618980** | **878542** |
| **Cash Flows from Investing Activities:** |  |  |
| &nbsp;&nbsp;Purchase of investments | (914842) | (336869) |
| &nbsp;&nbsp;Sale of investments | 35000 | 15761 |
| &nbsp;&nbsp;Maturity and paydowns of investments | 299243 | 155906 |
| &nbsp;&nbsp;Purchase of property, equipment and capitalized software | (8794) | (9026) |
| &nbsp;&nbsp;Change in restricted deposits | (860) |  |
| **Net cash used in investing activities** | **(590253)** | **(174228)** |
| **Cash Flows from Financing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Payments of debt issuance costs | (4739) |  |
| &nbsp;&nbsp;&nbsp;Tax payments related to net settlement of share-based awards |  | (855) |
| &nbsp;&nbsp;Proceeds from exercise of stock options | 1139 | 5728 |
| **Net cash (used in) provided by financing activities** | **(3600)** | **4873** |
| **Increase in cash, cash equivalents and restricted cash equivalents** | **2025127** | **709187** |
| Cash, cash equivalents, restricted cash and cash equivalents—beginning of period | 2804123 | 1551118 |
| **Cash, cash equivalents**, **restricted cash and cash equivalents—end of period** | **4829250** | **2260305** |
| Cash and cash equivalents | 4805139 | 2236555 |
| Restricted cash and cash equivalents included in restricted deposits | 24111 | 23750 |
| **Total cash, cash equivalents and restricted cash and cash equivalents** | $**4829250** | $**2260305** |
| **Supplemental Disclosures:** |  |  |
| Interest payments | $4177 | $154 |
| Income tax payments | $44 | $— |

---

See the accompanying Notes to Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Oscar Health, Inc.**

**Notes to Condensed Consolidated Financial Statements (unaudited)**

(in thousands, except per share amounts, or as otherwise stated herein)

**1.&nbsp;&nbsp;&nbsp;&nbsp;ORGANIZATION**

Oscar Health, Inc., together with its subsidiaries (either individually or collectively referred to as "Oscar" or the "Company"), is a leading healthcare technology company whose mission is to make a healthier life accessible and affordable for all. The Company's Class A common stock is traded on the New York Stock Exchange ("NYSE") under the symbol "OSCR".

Oscar operates as one reportable segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act ("ACA") and leverages its technology platform to provide services via its +Oscar offering. The Company also wholly owns three businesses operating in the individual market (collectively, the "Marketplace Subsidiaries"): Lucie, Inc. (formerly known as INSXCloud, Inc.), a technology enrollment platform for consumers, employers and brokers, Trove Group Inc. (formerly known as IHC Specialty Benefits, Inc.), an insurance agency that sells individual medical and supplemental health products, and HealthInsurance.org, LLC, a lead generation website providing educational content to help consumers navigate health insurance as well as the ACA and Medicare marketplaces.

The Company's member-first philosophy and innovative approach to care has earned the trust of approximately 3.2 million effectuated members ("members"), as of March 31, 2026. Effectuated members are those who are actively enrolled in one of the Company's plans and whose required premium payments have either been made or are within the payment grace period.

***Basis of Presentation***

The accompanying interim Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission for interim financial information. As such, these financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statements.

These Condensed Consolidated Financial Statements are unaudited; however, in the opinion of management, they reflect all adjustments, consisting only of normal recurring adjustments, necessary to state fairly the information presented in conformity with U.S. GAAP applicable for the interim periods presented. The results of operations for the interim periods presented are not necessarily indicative of results for the full year or future periods. These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and related notes thereto included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2025.

Certain monetary amounts, percentages, and other figures included in this Quarterly Report on Form 10-Q have been subject to rounding adjustments. Percentage amounts included in this Quarterly Report on Form 10-Q have not in all cases been calculated on the basis of such rounded figures, but on the basis of such amounts prior to rounding. For this reason, percentage amounts in this Quarterly Report on Form 10-Q may vary from those obtained by performing the same calculations using the figures in the Company's Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q. Certain other amounts that appear in this Quarterly Report on Form 10-Q may not sum due to rounding.

***Use of Estimates***

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Significant estimates inherent in the preparation of the accompanying interim Condensed Consolidated Financial Statements include healthcare costs incurred but not yet reported ("IBNR") and risk adjustment transfers. Estimates are based on past experience, evaluation of current trends, information from third-party professionals, and other considerations that are reasonable under the circumstances. Actual results may differ materially from these estimates.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

***Reclassification***

Certain prior period amounts have been reclassified within the components of total current assets and total current liabilities in the Company's Condensed Consolidated Balance Sheets, as well as within cash flows from operating activities in the Condensed Consolidated Statements of Cash Flows, to conform to the current period presentation. These reclassifications had no impact on the previously reported totals for current assets, current liabilities, or net cash provided by operating activities.

***Accounting Pronouncements - Not Yet Adopted***

In November 2024, the FASB issued Accounting Standards Update No. 2024-03 ("ASU 2024-03"), *Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses*, which requires additional disclosures in the Notes to Consolidated Financial Statements, disaggregating specific expense categories for relevant income statement captions and additional disclosures of the Company's total amount of selling expenses. This guidance is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. While the standard will require additional disclosures related to the Company's income statement, the standard is not expected to have any material impact on the Company's consolidated operating results, financial condition, or cash flows. The Company is currently evaluating the impact of the adoption of this guidance on the related disclosures.

In September 2025, the FASB issued Accounting Standards Update No. 2025-06 ("ASU 2025-06"), Intangibles–Goodwill and Other – Internal-Use Software (Subtopic 350-40): *Targeted Improvements to the Accounting for Internal-Use Software,* which modernizes the recognition and disclosure framework for internal-use software costs, removing all references to "development stages" and introducing a more judgment-based approach. This guidance is effective for annual periods beginning after December 15, 2027, and interim periods within those annual reporting periods. This ASU is applicable to the Company's fiscal year beginning January 1, 2028, with early application permitted. The transition method may be prospective, modified, or retrospective. The Company is currently evaluating the impact of the adoption of this guidance on the Company's consolidated financial statements and disclosures.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**2.&nbsp;&nbsp;&nbsp;&nbsp;EARNINGS PER SHARE** 

Basic earnings per share ("EPS") is computed by dividing Net income (loss) attributable to Oscar Health, Inc. for the period by the weighted-average shares of common stock outstanding during the period.

In periods when the Company is in a net loss position, potentially dilutive securities are excluded from the computation of diluted EPS because their inclusion would have an anti-dilutive effect; thus, basic EPS is the same as diluted EPS.

During periods of net income, diluted EPS is computed by adjusting Net income attributable to Oscar Health, Inc. for any interest charges, net of tax, related to the Company's convertible notes, as well as for the changes in the fair value of the bifurcated conversion option to the extent these instruments are dilutive. This adjusted net income is then divided by the sum of the basic weighted-average shares of common stock outstanding and any dilutive potential common stock outstanding during the period, using the treasury stock method and the if-converted method for convertible senior notes, as described in *"Note 9 - Debt."* Potential common stock includes the effect of outstanding dilutive stock options, restricted stock units, and performance-based restricted stock units. The computations for basic and diluted EPS are as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands, except per share data) | **2026** | **2025** |
| **<u>Numerator</u>:**  |  |  |
| Net income attributable to Oscar Health, Inc. - basic | $678996 | $275271 |
| Effect of convertible senior notes | 3721 | 5486 |
| **Net income available to Oscar Health, Inc. common shareholders - diluted** | $**682717** | $**280757** |
| **<u>Denominator</u>:** |  |  |
| Weighted average shares of common stock outstanding - basic | 298184 | 251279 |
| Common stock equivalents | 10840 | 18007 |
| Effect of convertible senior notes | 20727 | 36652 |
| **Weighted average shares of common stock outstanding - diluted** | **329751** | **305938** |
| **Earnings per Share** |  |  |
| **Basic**  | $**2.28** | $**1.10** |
| **Diluted** | $**2.07** | $**0.92** |

---

The following potential common shares were excluded from the computation of diluted EPS because including them would have had an anti-dilutive effect:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands) | **2026** | **2025** |
| Stock options to purchase common stock | 2428 | 3712 |
| Restricted stock units | 3574 | 4240 |
| Performance-based restricted stock units | 626 |  |
| **Total** | **6628** | **7952** |

---

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**3.&nbsp;&nbsp;&nbsp;&nbsp;REVENUE RECOGNITION**

***Premiums Earned***

Premium revenue includes premium subsidies received from the federal government, policy premiums collected directly from members, and assumed policy premiums earned as part of the reinsurance arrangement under the Cigna+Oscar Small Group plan previously offered, net of risk adjustment transfers and ceded premiums from reinsurance contracts accounted for under reinsurance accounting (See *"Note 10 - Reinsurance"* for additional information on the Company's reinsurance contracts).

The Company receives a fixed premium per member per month and recognizes premium revenue during the period in which it is obligated to provide services to its members. For direct policy premiums, revenue is recognized based on membership and eligibility criteria provided by the Centers for Medicare & Medicaid Services ("CMS") and is subject to monthly retroactive adjustment. Premium revenue is recorded net of adjustment for premium expected to be returned to CMS as a result of expected member disenrollments. These adjustments typically result from non-payment of premiums or the removal of members by CMS in connection with program integrity requirements and fraud, waste and abuse laws and regulations.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands) | **2026** | **2025** |
| Direct policy premiums | $6030275 | $3349671 |
| Risk adjustment transfers | (1442811) | (373749) |
| Reinsurance premiums ceded | (5618) | (2542) |
| Assumed premiums <sup>(1)</sup> | (984) | 22441 |
| **Premium** | $**4580862** | $**2995821** |
| (1) The Company did not renew the Cigna+Oscar Small Group arrangement with Cigna Health and Life Insurance Company after its initial term ended on December 31, 2024. Following termination, the Company has been providing transition and run-off services, and will continue to provide such services through December 31, 2026. The Company also continues to share in premiums and claims for plans sold or issued prior to December 15, 2024. | (1) The Company did not renew the Cigna+Oscar Small Group arrangement with Cigna Health and Life Insurance Company after its initial term ended on December 31, 2024. Following termination, the Company has been providing transition and run-off services, and will continue to provide such services through December 31, 2026. The Company also continues to share in premiums and claims for plans sold or issued prior to December 15, 2024. | (1) The Company did not renew the Cigna+Oscar Small Group arrangement with Cigna Health and Life Insurance Company after its initial term ended on December 31, 2024. Following termination, the Company has been providing transition and run-off services, and will continue to provide such services through December 31, 2026. The Company also continues to share in premiums and claims for plans sold or issued prior to December 15, 2024. |

---

The direct policy premiums earned from CMS for the three months ended March 31, 2026 and March 31, 2025 of $5.5 billion, and $3.1 billion, respectively, are net of premium subsidies refunded or estimated premium subsidies expected to be refunded to CMS. The amount of premium subsidies expected to be refunded as of March 31, 2026 and December 31, 2025 of $665.4 million and $138.1 million, respectively, is included within Payables to CMS on the Condensed Consolidated Balance Sheets.

***Other Revenues***

Other revenues include revenue earned through our Marketplace Subsidiaries, fees for services performed via the +Oscar platform, revenue sharing from virtual credit card rebates, and sublease income. Other revenue is recognized in the period the contractual performance obligations are satisfied and measured in an amount that reflects the consideration the Company expects to be entitled to in exchange for performing the services. The timing of the Company's revenue recognition may differ from the timing of payment by customers. A receivable is recorded to Premiums and accounts receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, deferred revenue is recorded to Accounts payable and other liabilities when payment is received before the performance obligations are satisfied.

**4.&nbsp;&nbsp;&nbsp;&nbsp;INVESTMENTS**

Net investment income was attributable to the following:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands) | **2026** | **2025** |
| Fixed maturity securities | $27450 | $27218 |
| Cash equivalents | 33633 | 18559 |
| Other <sup>(1)</sup>  | 51 | 634 |
| Investment income | 61134 | 46411 |
| Investment expense | (520) | (299) |
| **Net investment income** | $**60614** | $**46112** |

---

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

(1) Represents the net interest earned on funds withheld.

As of March 31, 2026 and December 31, 2025, the Company recorded accrued investment income of $23.1 million and $20.2 million, respectively.

The following tables provide summaries of the Company's carrying amounts and fair values of available-for-sale securities by major security type as of March 31, 2026 and December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| (in thousands) | **Amortized Cost** | **Unrealized Gains** | **Unrealized Losses** | **Fair Value** |
| U.S. treasury and agency securities | $2090884 | $7692 | $(2781) | $2095795 |
| Corporate notes | 483431 | 721 | (716) | 483436 |
| Certificates of deposit | 650000 |  |  | 650000 |
| Asset-backed securities | 28209 | 70 |  | 28279 |
| Other <sup>(1)</sup>  | 3909 |  |  | 3909 |
| **Total** | $**3256433** | $**8483** | $**(3497)** | $**3261419** |

---

(1) Includes equity securities without a readily determinable market value.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| (in thousands) | **Amortized Cost** | **Unrealized Gains** | **Unrealized Losses** | **Fair Value** |
| U.S. treasury and agency securities | $2076112 | $15433 | $(565) | $2090980 |
| Corporate notes | 557413 | 3051 | (50) | 560414 |
| Asset-backed securities | 33497 | 148 |  | 33645 |
| Other <sup>(1)</sup>  | 2409 |  |  | 2409 |
| **Total** | $**2669431** | $**18632** | $**(615)** | $**2687448** |

---

(1) Includes equity securities without a readily determinable market value.

The following tables present the estimated fair value and gross unrealized losses of fixed maturity securities in a gross unrealized loss position, by the length of time in which the securities have continuously been in that position, as of March 31, 2026 and December 31, 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | **Less than 12 Months** | **Less than 12 Months** | **Less than 12 Months** | **12 Months or Longer** | **12 Months or Longer** | **12 Months or Longer** |
| (in thousands, except no. of securities) | **Number of Securities** | **Fair Value** | **Gross <br>Unrealized Losses** | **Number of Securities** | **Fair Value** | **Gross <br>Unrealized Losses** |
| U.S. treasury and agency securities | 139 | $824969 | $(2568) | 3 | $29976 | $(214) |
| Corporate notes | 131 | 215882 | (715) |  |  |  |
| **Total** | **270** | $**1040851** | $**(3283)** | **3** | $**29976** | $**(214)** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Less than 12 Months** | **Less than 12 Months** | **Less than 12 Months** | **12 Months or Longer** | **12 Months or Longer** | **12 Months or Longer** |
| (in thousands, except no. of securities) | **Number of Securities** | **Fair Value** | **Gross <br>Unrealized Losses** | **Number of Securities** | **Fair Value** | **Gross <br>Unrealized Losses** |
| U.S. treasury and agency securities | 48 | $265431 | $(445) | 5 | $40784 | $(120) |
| Corporate notes | 59 | 82246 | (50) |  |  |  |
| **Total** | **107** | $**347677** | $**(495)** | **5** | $**40784** | $**(120)** |

---

The Company monitors available-for-sale debt securities for credit losses and recognizes an allowance for credit losses when factors indicate a decline in the fair value of a security is credit-related. Certain investments may experience a decline in fair value due to changes in market interest rates, changes in general economic conditions, or a deterioration in the credit worthiness of a security's issuer. For securities in an unrealized loss position that the Company does not intend to sell, the

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

Company has assessed the gross unrealized losses during the period and determined an allowance for credit losses is not necessary because the declines in fair value are believed to be due to market fluctuations and not due to credit-related events.

The amortized cost and fair value of the Company's fixed maturity securities as of March 31, 2026 and December 31, 2025 by contractual maturity are shown below. Actual maturities of these securities could differ from their contractual maturities because issuers may have the right to call or prepay obligations, with or without penalties.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** |
| (in thousands) | **Amortized Cost** | **Fair Value** | **Amortized Cost** | **Fair Value** |
| Due in one year or less | $1993289 | $1994644 | $1213011 | $1216461 |
| Due after one year through five years | 1168394 | 1172143 | 1372038 | 1385735 |
| Due after five years through ten years | 90841 | 90723 | 81973 | 82843 |
| **Total** | $**3252524** | $**3257510** | $**2667022** | $**2685039** |

---

**5.&nbsp;&nbsp;&nbsp;&nbsp;FAIR VALUE MEASUREMENTS**

Fair value represents the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. The Company's financial assets and liabilities measured at fair value on a recurring basis are categorized into a three-level fair value hierarchy based on the priority of the inputs used in the fair value valuation technique.

The levels of the fair value hierarchy are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Level 1</u>: Inputs utilize quoted (unadjusted) prices in active markets for identical assets or liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Level 2</u>: Inputs utilize quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations in which all significant inputs are observable in active markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>Level 3</u>: Inputs utilized are unobservable but significant to the fair value measurement for the asset or liability. The unobservable inputs are used to measure fair value to the extent relevant observable inputs are not available. The unobservable inputs typically reflect management's own estimates about the assumptions a market participant would use in pricing the asset or liability.

The following tables summarize fair value measurements by level for assets and liabilities measured at fair value on a recurring basis:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| (in thousands) | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Assets** |  |  |  |  |
| &nbsp;&nbsp;Cash equivalents | $136313 | $1793 | $— | $138106 |
| &nbsp;&nbsp;Investments |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. treasury and agency securities | $— | $2095795 | $— | $2095795 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate notes |  | 483436 |  | 483436 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates of deposit | 650000 |  |  | 650000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset-backed securities |  | 28279 |  | 28279 |
| &nbsp;&nbsp;Restricted investments |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. treasury securities |  | 4520 |  | 4520 |
| &nbsp;&nbsp;&nbsp;**Total assets** | $**786313** | $**2613823** | $**—** | $**3400136** |

---

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| (in thousands) | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Assets** |  |  |  |  |
| &nbsp;&nbsp;Cash equivalents | $49552 | $— | $— | $49552 |
| &nbsp;&nbsp;Investments |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. treasury and agency securities | $— | $2090980 | $— | $2090980 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate notes |  | 560414 |  | 560414 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset-backed securities |  | 33645 |  | 33645 |
| &nbsp;&nbsp;&nbsp;Restricted investments |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. treasury securities |  | 2979 |  | 2979 |
| &nbsp;&nbsp;&nbsp;**Total assets** | $**49552** | $**2688018** | $**—** | $**2737570** |

---

**6.&nbsp;&nbsp;&nbsp;&nbsp;RESTRICTED CASH AND RESTRICTED DEPOSITS**

The Company maintains cash, cash equivalents, and investments on deposit that are pledged to various state agencies in connection with its insurance licensure or property leases. The restricted cash and cash equivalents and restricted investments presented below are included in Restricted deposits in the accompanying Condensed Consolidated Balance Sheets.

---

| | | |
|:---|:---|:---|
| (in thousands) | **March 31, 2026** | **December 31, 2025** |
| Restricted cash and cash equivalents | $24111 | $29972 |
| Restricted investments | 4520 | 2979 |
| **Restricted deposits** | $**28631** | $**32951** |

---

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**7.&nbsp;&nbsp;&nbsp;&nbsp;BENEFITS PAYABLE**

Reserves for medical claims expenses are estimated using actuarial assumptions and recorded as Benefits payable liabilities on the Condensed Consolidated Balance Sheets. The assumptions for the estimates and for establishing the resulting liability are reviewed and any adjustments to reserves are reflected in the Condensed Consolidated Statements of Operations in the period in which the estimates are updated.

The following table provides a rollforward of the Company's beginning and ending benefits payable and claims adjustment expenses ("CAE") payable balances for the three months ended March 31, 2026 and 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| (in thousands) | **Benefits Payable** | **Unallocated Claims <br>Adjustment Expense** | **Total** | **Benefits Payable** | **Unallocated Claims <br>Adjustment Expense** | **Total** |
| Benefits payable, beginning of the period | $1455385 | $19310 | $1474695 | $1356730 | $18241 | $1374971 |
| Less: Reinsurance recoverable | 26541 |  | 26541 | 58635 |  | 58635 |
| **Benefits payable, beginning of the period, net** | $**1428844** | $**19310** | $**1448154** | $**1298095** | $**18241** | $**1316336** |
| Claims incurred and CAE |  |  |  |  |  |  |
| Current year | $3381201 | $18317 | $3399518 | $2377506 | $28933 | $2406439 |
| Prior years | (151344) |  | (151344) | (117855) |  | (117855) |
| **Total claims incurred and CAE, net** | $**3229857** | $**18317** | $**3248174** | $**2259651** | $**28933** | $**2288584** |
| Claims paid and CAE |  |  |  |  |  |  |
| Current year | $2257289 | $7328 | $2264617 | $1536660 | $17753 | $1554413 |
| Prior years | 715766 | 7720 | 723486 | 588857 | 9969 | 598826 |
| **Total claims and CAE paid, net** | $**2973055** | $**15048** | $**2988103** | $**2125517** | $**27722** | $**2153239** |
| Benefits and CAE payable, end of period, net | $1685646 | $22579 | $1708225 | $1432229 | $19452 | $1451681 |
| Add: Reinsurance recoverable | 48405 |  | 48405 | 33349 |  | 33349 |
| **Benefits and CAE payable, end of period** | $**1734051** | $**22579** | $**1756630** | $**1465578** | $**19452** | $**1485030** |

---

Amounts incurred related to prior periods vary from previously estimated liabilities as more claim information becomes available and claims are ultimately settled. The favorable prior period development recognized in the three months ended March 31, 2026 resulted primarily from lower than expected paid claims for 2025.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**8.&nbsp;&nbsp;&nbsp;&nbsp;RISK ADJUSTMENT**

The risk adjustment programs in the markets the Company serves are administered federally by CMS and are designed to mitigate the potential impact of adverse selection and provide stability for health insurers. Under these programs, each plan is assigned a risk score based upon demographic information and current year claims information related to its members. Plans with lower than average risk scores generally pay into the pool (included within Payables to CMS on the Condensed Consolidated Balance Sheets), while plans with higher than average risk scores generally receive distributions (included within Receivables from CMS on the Condensed Consolidated Balance Sheets). The Company estimates its risk adjustment transfer receivable or payable for each state by comparing its estimated risk score to the state average risk score. The Company records a receivable or payable as an adjustment to its premium revenues to reflect the year-to-date impact of the risk adjustment based on its best estimate. The Company reevaluates its risk adjustment transfer estimates as new information and market data becomes available until final reporting is received from CMS in later periods, which may be up to twelve months in arrears.

The following table provides a rollforward of the Company's beginning and ending risk adjustment receivable and payable balances for the three months ended March 31, 2026 and 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| (in thousands) | **Risk Adjustment Receivable** | **Risk Adjustment Payable** | **Net Risk Adjustment Payable** | **Risk Adjustment Receivable** | **Risk Adjustment Payable** | **Net Risk Adjustment Payable** |
| **Beginning balance** <sup>(1)</sup> | $**56066** | $**2587700** | $**2531634** | $**64779** | $**1558341** | $**1493562** |
| Change in accrual: |  |  |  |  |  |  |
| Current year | $16112 | $1374310 | $1358198 | $25666 | $306870 | $281204 |
| Prior years <sup>(2)</sup> | 5132 | 89745 | 84613 | (3319) | 89240 | 92559 |
| **Change in accrual, net** | $**21244** | $**1464055** | $**1442811** | $**22347** | $**396110** | $**373763** |
| **Ending balance:** |  |  |  |  |  |  |
| Current year | $16112 | $1374310 | $1358198 | $25666 | $306870 | $281204 |
| Prior years | 61198 | 2677445 | 2616247 | 61460 | 1647581 | 1586121 |
| **Ending balance** | $**77310** | $**4051755** | $**3974445** | $**87126** | $**1954451** | $**1867325** |

---

(1)The table includes risk adjustment data validation ("RADV") receivables and payables. The balance at the beginning of each year presented pertains to prior policy years.

(2)Includes immaterial payments for prior policy years.

The three months ended March 31, 2026, reflected lower claims per member with an assumption of higher offsetting risk adjustment payables, as compared to the three months ended March 31, 2025.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**9.&nbsp;&nbsp;&nbsp;&nbsp;DEBT** 

***2031 Convertible Senior Notes***

In February 2022, the Company issued $305.0 million in aggregate principal amount of convertible senior notes due 2031 (the "2031 Notes") in a private placement to funds affiliated with or advised by Dragoneer Investment Group, LLC, Thrive Capital, LionTree Investment Management, LLC, and Tenere Capital LLC (the "Initial Purchasers"). In connection with the issuance of the 2031 Notes, on January 27, 2022, the Company entered into an investment agreement with the Initial Purchasers (the "Investment Agreement") and on February 3, 2022, the Company entered into an indenture with U.S. Bank, as Trustee (the "2031 Indenture").

On September 11, 2025, the Company entered into an amendment to the Investment Agreement to permit the private offering of the 2030 Notes (as defined below) under the Investment Agreement (the "Amendment"). The Amendment provided, in relevant part, that the issuance of the 2030 Notes would be permitted provided that the 2030 Notes were and remained expressly subordinated in right of payment to the 2031 Notes for as long as Oasis FD Holdings, LP ("Dragoneer") held at least $75.0 million in aggregate principal amount of the 2031 Notes. As discussed further below, in connection with the Exchange Agreement and the related transactions, as of November 5, 2025, the debt covenants in the Investment Agreement, as amended, were extinguished, and the 2030 Notes ceased to be subordinated to the 2031 Notes.

The 2031 Notes bear interest at a rate of 7.25% per annum, payable in cash, semi-annually in arrears on June 30 and December 31 of each year, commencing on June 30, 2022. The 2031 Notes will mature on December 31, 2031, subject to earlier repurchase, redemption, or conversion, as further discussed in "*Note 9 - Debt*," in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

The 2031 Notes are initially convertible into the Company's Class A common stock at a price of approximately $8.32 per share of Class A common stock (based on an initial conversion rate of 120.1721 per $1,000 principal amount), subject to customary adjustments upon the occurrence of certain events. The holders may elect to convert their 2031 Notes if certain conditions are met, as further discussed in "*Note 9 - Debt,*" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, including upon the satisfaction of a Class A common stock sale price condition. During the quarterly period ended March 31, 2026, the Class A common stock sales price condition was satisfied because the last reported sales price per share of the Company's common stock exceeded 130% of the conversion price of $8.32 per share for twenty (20) trading days of the thirty (30) consecutive trading days ending on the last trading day of the quarter. As a result, the holders may elect to convert their 2031 Notes during the second quarter of 2026.

As of March 31, 2026, $35 million aggregate principal amount of the 2031 Notes remained outstanding.

***2030 Convertible Senior Notes***

On September 18, 2025, the Company issued $410.0 million aggregate principal amount of convertible senior notes due 2030 (the "2030 Notes"). The 2030 Notes were issued pursuant to an indenture (the "2030 Indenture"), dated as of September 18, 2025, between the Company and U.S. Bank Trust Company, National Association, as trustee.

The 2030 Notes are the Company's unsecured indebtedness which bear interest at a rate of 2.25% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2026. The 2030 Notes will mature on September 1, 2030, unless they are earlier repurchased, redeemed, or converted, as further discussed in "*Note 9 - Debt*," in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

As discussed above under *"–2031 Convertible Senior Notes"*, the 2030 Notes were originally subordinated to the 2031 Notes. In connection with the Exchange Agreement and the related transactions, as of November 5, 2025, the 2030 Notes ceased to be subordinated to the 2031 Notes.

As of March 31, 2026, $410 million aggregate principal amount of the 2030 Notes remained outstanding.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

The following is a summary of net carrying amounts and the estimated fair values of the Company's convertible notes:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2030 Notes** | **2030 Notes** | **2031 Notes** | **2031 Notes** |
| (in thousands) | **March 31, 2026** | **December 31, 2025** | **March 31, 2026** | **December 31, 2025** |
| Principal amount | $410000 | $410000 | $35000 | $35000 |
| Unamortized debt discount and issuance costs | $12640 | $13356 | $1484 | $1549 |
| Net carrying amount | $397360 | $396644 | $33516 | $33451 |
| Estimated fair value | $366335 | $401431 | $57839 | $63997 |
| Leveling | Level 2 | Level 2 | Level 3 | Level 3 |

---

The following table presents the interest expense over the term of the Company's convertible notes:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands) | **2026** | **2025** |
| Coupon interest expense | $2940 | $5528 |
| Amortization of debt discount and issuance costs | 781 | 194 |
| **Interest expense** | $**3721** | $**5722** |

---

***Capped Call Transactions***

On September 15, 2025, in connection with the pricing of the offering of 2030 Notes, the Company entered into privately negotiated capped call transactions (the "Base Capped Call Transactions") with certain of the 2030 Notes initial purchasers or their affiliates and certain other financial institutions (the "Option Counterparties"). In addition, on September 16, 2025, in connection with the initial purchasers' exercise of their option to purchase additional 2030 Notes, the Company entered into additional capped call transactions (the "Additional Capped Call Transactions," and, together with the Base Capped Call Transactions, (the "Capped Call Transactions") with each of the Option Counterparties. The cost of the Capped Call Transactions was approximately $34.4 million. For more information, see "*Note 9 - Debt*," in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

***2026 Revolving Credit Facilit***y

On February 6, 2026, Oscar Health, Inc. entered into a $475.0 million secured three-year revolving credit facility (the "Revolving Credit Facility"), pursuant to a Credit Agreement (the "2026 Credit Agreement") by and among the Company, certain subsidiaries of the Company, as subsidiary guarantors, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto. The facility is set to expire on February 6, 2029, and includes the ability for the Company to increase commitments up to an additional $100.0 million, subject to customary closing conditions. Proceeds will be used for general corporate purposes. Borrowings will initially bear interest, at the Company's option, at either the Term Secured Overnight Financing Rate ("SOFR") plus 4.50% per annum or the Alternate Base Rate plus 3.50% per annum. Starting June 30, 2026, each of the commitment fee (initially 0.50% for available but undrawn amounts) and applicable interest rate margin will be adjusted based on the Company's Total Net Leverage Ratio. The 2026 Credit Agreement contains customary conditions precedent, representations and warranties, affirmative and negative covenants, events of default and indemnities. In addition, the 2026 Revolving Credit Facility requires compliance with certain financial covenants. As of March 31, 2026, no borrowings were outstanding under the Revolving Credit Facility.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**10.&nbsp;&nbsp;&nbsp;&nbsp;REINSURANCE**

The Company participates in quota share reinsurance to limit risk and capital requirements and XOL reinsurance to mitigate the exposure of high cost or catastrophic member risk. The quota share reinsurance arrangements are with more than one counterparty with multiple state-level treaties. The XOL reinsurance arrangements are with a private counterparty and federal and state-run programs. A summary of the Company's reinsurance agreements and related accounting treatment is included in *"Note 11 - Reinsurance,"* in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

As previously disclosed in *"Note 1 - Organization,"* in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, the Company did not renew the Cigna+Oscar Small Group arrangement after the expiration of the initial term on December 31, 2024, and will continue to provide transition and run-off services through December 31, 2026, and share proportionally in all premiums and claims for any Cigna+Oscar Small Group plan sold or issued on or before December 15, 2024, in accordance with the terms of the arrangement.

***Reinsurance Contracts Accounted for under Deposit Accounting***

Reinsurance contracts that do not meet risk transfer requirements are accounted for under the deposit accounting method. Under deposit accounting, the contract is recorded as a financing transaction, with no impact to premium revenues or medical expenses. The premiums earned and claims incurred that would have otherwise been ceded under reinsurance accounting are recorded on a net basis on the Consolidated Balance Sheets as a deposit liability within Accounts payable and other liabilities. As of March 31, 2026 and December 31, 2025, a deposit liability balance of $154.2 million and $140.5 million, respectively, was recorded for the Company's quota share arrangements accounted for under deposit accounting. For the three months ended March 31, 2026 and March 31, 2025, the deposit accounting impact, net of ceding commission, of $21.9 million and $11.3 million, respectively, were recognized within Selling, general, and administrative expenses on the Condensed Consolidated Statements of Operations.

For the three months ended March 31, 2026, and 2025, the Company ceded 47% and 50% of its premiums under reinsurance contracts accounted for under deposit accounting, respectively.

***Reinsurance Contracts Accounted for under Reinsurance Accounting***

The Company applies reinsurance accounting primarily to XOL treaties. The tables below present information for the Company's reinsurance arrangements accounted for under reinsurance accounting. Please see *"Note 3 - Revenue Recognition"* for total reinsurance premiums ceded and reinsurance premiums assumed, which are included as components of total Premium revenue in the Condensed Consolidated Statements of Operations.

The following table reconciles total Medical expenses to the amount presented in the Condensed Consolidated Statements of Operations:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands) | **2026** | **2025** |
| Direct claims incurred | $3293837 | $2268284 |
| Ceded reinsurance claims | (62684) | (31012) |
| Assumed reinsurance claims | (1296) | 22379 |
| **Medical expenses** | $**3229857** | $**2259651** |

---

The composition of the Reinsurance recoverable balance on the Consolidated Balance Sheets is as follows:

---

| | | |
|:---|:---|:---|
| (in thousands) | **March 31, 2026** | **December 31, 2025** |
| Reinsurance premium and claim recoverables | $140750 | $98014 |
| Reinsurance ceding commissions | 7003 | 7002 |
| Experience refunds on reinsurance agreements | (5266) | (5266) |
| **Reinsurance recoverable** | $**142487** | $**99750** |

---

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

***Credit Ratings***

The financial condition of the Company's reinsurers is regularly evaluated to minimize exposure to significant losses. A key credit quality indicator for reinsurance is the financial strength ratings issued by the credit rating agencies, which provide an independent opinion of a reinsurer's ability to meet ongoing obligations to policyholders. The Company's reinsurers have most recently been issued financial strength ratings of A+ or higher.

The creditworthiness of each reinsurer is evaluated in order to assess counterparty credit risk and estimate an allowance for expected credit losses on the Company's reinsurance recoverable balances.

**11.&nbsp;&nbsp;&nbsp;&nbsp;RELATED PARTY TRANSACTIONS** 

In February 2022, the Company issued the 2031 Notes to funds affiliated with or advised by Dragoneer Investment Group, LLC, Thrive Capital Management, LLC, LionTree Investment Management, LLC and Tenere Capital LLC (collectively, the "Purchasers"). See *"Note 9 - Debt"* for additional information. On November 3, 2025, the Company and Dragoneer entered into an Exchange Agreement (the "Exchange Agreement"), allowing Dragoneer to exchange up to $250.0 million of 2031 Notes for Class A common stock and up to $17.8 million in cash and/or stock. In November 2025, Dragoneer exchanged all $250.0 million of its 2031 Notes for approximately 30.1 million shares of Class A common stock and an inducement payment of approximately $17.8 million ($4.4 million in cash and $13.3 million settled through the issuance of approximately 0.7 million additional shares of Class A common stock). In connection with the Exchange Agreement and the related transactions, as of November 5, 2025, the debt covenants in the Investment Agreement were extinguished, and the 2030 Notes ceased to be subordinated to the 2031 Notes.

On April 3, 2026 (the "Purchase Date"), the Company entered into a Stock Purchase Agreement with Mark T. Bertolini, the Company's Chief Executive Officer, pursuant to which the Company sold an aggregate of 1,000,000 shares of the Company's Class A common stock (the "Shares") to Mr. Bertolini for an aggregate purchase price of $11.9 million, at a price per share of $11.92, representing the per share closing price of the Company's Class A common stock as reported by the NYSE on the trading date immediately preceding the Purchase Date. No underwriting discounts or commissions were paid in connection with the transaction. The Shares were offered and sold in reliance upon the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction not involving a public offering.

 **12.&nbsp;&nbsp;&nbsp;&nbsp;COMMITMENTS AND CONTINGENCIES**

The Company's current and past business practices are subject to reviews or other investigations by various state insurance and healthcare regulatory authorities and other state and federal regulatory authorities. These reviews focus on numerous facets of the Company's business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, network adequacy, utilization management practices, pharmacy benefits, access to care, compliance with Health Insurance Marketplace or enhanced direct enrollment ("EDE") agreements, and sales practices, among others. Some of these reviews have historically resulted in fines imposed on the Company and some have required changes to certain of the Company's practices. The Company continues to be subject to these reviews, which could result in additional fines or other sanctions being imposed on the Company or additional changes to certain of its practices.

The Company is also currently involved in, and may in the future from time to time become involved in, legal proceedings and other claims in the ordinary course of its business, including class actions and suits brought by the Company's members, providers, commercial counterparties, employees, and other parties relating to the Company's business, including management and administration of health benefit plans and other services. Such matters can include claims relating to the performance of contractual and non-contractual obligations to providers, vendors, members, employer groups, and others, including, but not limited to, the alleged failure to properly pay in-network and out-of-network claims and challenges to the manner in which the Company processes claims, claims alleging that the Company has engaged in unfair business practices, disputes regarding the amounts owed under vendor contracts, various employment claims, disputes regarding reinsurance arrangements, disputes relating to intellectual property, privacy, the Telephone Consumer Protection Act and class action lawsuits, or other, claims alleging that the Company has engaged in unfair business practices.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

The Company records liabilities for its reasonable estimates of probable losses resulting from these matters where appropriate. Estimates of losses resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred, the ultimate settlement of which could be material.

Given that such proceedings are subject to uncertainty, there can be no assurance that such legal proceedings, either individually or in the aggregate, will not have a material adverse effect on Oscar's business, results of operations, financial condition or cash flows.

The ACA originally established a cost-sharing reduction ("CSR") program to make health insurance more affordable for eligible individuals by requiring insurers to reduce out-of-pocket costs while receiving CSR subsidies from CMS. In 2017, the Trump Administration issued an executive order that immediately ceased payments of ACA CSR subsidies to issuers. On June 27, 2017, impacted issuers seeking compensation for the halted CSR subsidy payments commenced a class action lawsuit against the federal government in the Court of Federal Claims, captioned Common Ground Healthcare Cooperative v. United States, Case No. 17-877. In 2024, an agreement in principle was reached between class counsel on behalf of impacted issuers and the federal government to retroactively compensate the class. The settlement agreement was fully executed by the class and the federal government on August 11, 2025. On November 6, 2025, the Court of Federal Claims granted final settlement approval and ordered the distribution of 95% of the settlement funds, with the remaining 5% held until the attorneys' fees award is determined. The estimated net recovery recorded as of December 31, 2025 was approximately $48 million, which was subsequently received in April 2026.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**13.&nbsp;&nbsp;&nbsp;&nbsp;SEGMENT INFORMATION** 

The Company operates in and reports as a single reportable segment. The Company determined that the Chief Executive Officer is the chief operating decision maker ("CODM") who regularly reviews financial information and other key performance indicators on a consolidated basis, for the purposes of allocating resources and evaluating financial performance. Factors used in determining the reportable segment include the nature of operating activities, the Company's organizational and reporting structure, and the type of information presented to the Company's CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in *"Note 2 - Summary of Significant Accounting Policies*," in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. The CODM reviews Net income (loss) attributable to Oscar Health, Inc. and Earnings from operations presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. These metrics serve as benchmarks to evaluate the business, measure performance, identify trends, prepare financial projections, and make strategic decisions. The CODM does not evaluate performance or allocate resources based on segment assets data; therefore, total segment assets are not presented.

The following table presents the revenue, significant expenses, and net income (loss) for the Company's segment. As the Company operates and reports as a single segment, its measure of segment net income (loss) is the same as Net income (loss) attributable to Oscar Health, Inc. on the Condensed Consolidated Statements of Operations.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands) | **2026** | **2025** |
| **Total revenue** | $**4647194** | $**3046263** |
| Less: |  |  |
| Medical expenses | 3229857 | 2259651 |
| Selling, general, and administrative ("SG&A") expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Member acquisition and servicing costs <sup>(1)</sup> | 349646 | 235351 |
| &nbsp;&nbsp;&nbsp;&nbsp;Premium taxes, exchange fees, and other taxes and fees <sup>(2)</sup> | 196508 | 97635 |
| &nbsp;&nbsp;&nbsp;&nbsp;All other SG&A <sup>(3)</sup> | 160080 | 149773 |
| Total Selling, general, and administrative expenses | 706234 | 482759 |
| Depreciation and amortization | 7018 | 6730 |
| **Earnings from operations** | **704085** | **297123** |
| Interest expense | 5383 | 5994 |
| Other expenses (income) | (71) | 2918 |
| **Earnings before income taxes** | **698773** | **288211** |
| Income tax expense | 19750 | 12705 |
| Net income attributable to noncontrolling interests | 27 | 235 |
| **Net income attributable to Oscar Health, Inc.** | $**678996** | $**275271** |

---

(1)Member acquisition and servicing costs include the Company's expenses incurred to acquire, service, and fulfill obligations to members.

(2)Premium taxes, exchange fees, and other taxes and fees represent non-income tax charges from federal and state governments, including but not limited to healthcare exchange user fees and premium taxes.

(3)All other SG&A includes employee-related and administrative costs that are not member-based. Additionally, all other SG&A includes the net impact of quota share reinsurance accounted for under deposit accounting.

***Significant Customers***

The Company generates the majority of its total revenue from health insurance policy premiums, which primarily come from subsidies received from CMS as part of the Advanced Premium Tax Credit program.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the audited Consolidated Financial Statements and notes thereto and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") included in our Annual Report on Form 10-K for the year ended December 31, 2025 that was filed with the SEC on February 13, 2026. Unless the context otherwise requires, references in this MD&A to "we," "us," "our," "Oscar," "Oscar Health, Inc," and the "Company" mean the business and operations of Oscar Health, Inc. and its consolidated subsidiaries.*

**Index to this MD&A**

Management's discussion and analysis of financial condition and results of operations is comprised of the following sections:

---

| | |
|:---|:---|
| | **<u>Page</u>** |
| <u>[Overview](#ic0ed02a1d98540d0b02bc707fdf6e276_91)</u> | <u>[25](#ic0ed02a1d98540d0b02bc707fdf6e276_91)</u> |
| <u>[Recent Developments, Trends and Other Key Factors Impacting Performance](#ic0ed02a1d98540d0b02bc707fdf6e276_94)</u> | <u>[26](#ic0ed02a1d98540d0b02bc707fdf6e276_94)</u> |
| <u>[Critical Accounting Policies and Estimates](#ic0ed02a1d98540d0b02bc707fdf6e276_97)</u> | <u>[30](#ic0ed02a1d98540d0b02bc707fdf6e276_97)</u> |
| <u>[Components of](#ic0ed02a1d98540d0b02bc707fdf6e276_100)[O](#ic0ed02a1d98540d0b02bc707fdf6e276_100)[ur Results of Operations](#ic0ed02a1d98540d0b02bc707fdf6e276_100)</u> | <u>[30](#ic0ed02a1d98540d0b02bc707fdf6e276_100)</u> |
| <u>[Results of Operations](#ic0ed02a1d98540d0b02bc707fdf6e276_103)</u> | <u>[32](#ic0ed02a1d98540d0b02bc707fdf6e276_103)</u> |
| <u>[Liquidity and Capital Resources](#ic0ed02a1d98540d0b02bc707fdf6e276_106)</u> | <u>[34](#ic0ed02a1d98540d0b02bc707fdf6e276_106)</u> |

---

**Overview**

Oscar is a leading healthcare technology company built around a full stack technology platform and a relentless focus on member experience. We have been challenging the status quo in the healthcare system since our founding in 2012, and are dedicated to making a healthier life accessible and affordable for all. Oscar serves individuals, families, and employees through the Patient Protection and Affordable Care Act ("ACA"). We also offer health technology solutions that power the healthcare industry through +Oscar.

Our technology drives better choice, deeper engagement, and connection to high-value clinical care, earning us the trust of approximately 3.2 million effectuated members ("members") as of March 31, 2026, which represents an approximately 56% increase compared to March 31, 2025. Effectuated members are those who are actively enrolled in one of the Company's plans and whose required premium payments have either been made or are within the payment grace period. Refer to *"Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations-Recent Developments, Trends and Other Key Factors Impacting Performance-Members"*, for further discussion regarding our members.

The Company also wholly owns three businesses operating in the individual market (collectively, the "Marketplace Subsidiaries"): Lucie, Inc. (formerly known as INSXCloud, Inc.), a technology enrollment platform for consumers, employers and brokers; Trove Group Inc. (formerly known as IHC Specialty Benefits, Inc.), an insurance agency that sells individual medical and supplemental health products, and HealthInsurance.org, LLC, a lead generation website providing educational content to help consumers navigate health insurance as well as the ACA and Medicare marketplaces.

We regularly review our total revenue, medical loss ratio ("MLR"), selling, general, and administrative expense ratio ("SG&A expense ratio"), earnings from operations, and net income attributable to Oscar Health, Inc. to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions.

***Total Revenue***

Total revenue includes premium revenue (net of risk adjustment transfers), investment income, and other revenues. We believe total revenue is an important metric to assess the growth of our business, as well as the earnings potential of our investment portfolio.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

***MLR***

MLR is a metric used to calculate medical expenses as a percentage of net premiums before ceded quota share reinsurance. The impact of the federal risk adjustment program is included in the denominator of our MLR. We believe MLR is an important metric to demonstrate the ratio of our costs to pay for the healthcare of our members to the net premium before ceded quota share reinsurance.

***SG&A Expense Ratio***

The SG&A expense ratio reflects the Company's selling, general, and administrative expenses, as a percentage of total revenue (net of risk adjustment transfers). We believe the SG&A expense ratio is useful to evaluate our ability to manage our overall selling, general, and administrative cost base.

***Earnings from Operations***

Earnings from operations is the Company's total revenue less total operating expenses. We believe earnings from operations is an important metric for assessing operating performance.

***Net Income Attributable to Oscar Health, Inc.***

Net income attributable to Oscar Health, Inc. is net earnings allocated to the Company after net income attributable to noncontrolling interests. It is a key indicator of the Company's profitability and operational efficiency, allowing management to evaluate performance and make informed decisions on strategic planning, cost management, and resource allocation.

**Recent Developments, Trends and Other Key Factors Impacting Performance**

***Regulatory Update***

Our operations are subject to comprehensive and detailed federal, state, and local laws and regulations, which continue to rapidly evolve and change. The following regulatory developments have impacted our operations during the periods presented in the financial statements contained elsewhere in this Quarterly Report on Form 10-Q, or are expected to impact our results of operations in future periods.

*The ACA*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** The enhanced Advanced Premium Tax Credits ("eAPTCs") that were previously in place since 2021 contributed to increases in the population of the health insurance marketplaces established by the ACA and operated by the federal government, as well as other marketplaces operated by individual states (collectively, "Health Insurance Marketplaces"), as well as increases in our membership. These eAPTCs expired at the end of 2025, which we believe caused coverage to become unaffordable for some individuals, reducing both the overall participation in the Health Insurance Marketplaces and the Company's membership since the end of the 2026 open enrollment period ("OEP").

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Centers for Medicare & Medicaid Services ("CMS") is increasingly focused on improving integrity in the Health Insurance Marketplaces' eligibility and enrollment process, and we expect this focus to continue. During the second half of 2024, CMS enacted new measures to respond to increases in unauthorized changes in consumer enrollments by agents and brokers and to reduce consumer burdens related to unauthorized enrollments. While these measures are important to prevent unauthorized enrollments, they may also make it more difficult for individuals to complete valid enrollments in new plans, switch from one plan to another, or obtain Advanced Premium Tax Credits ("APTCs"). In addition, on June 25, 2025, CMS issued a rule that created stricter eligibility verification processes for APTCs, as well as other requirements related to ACA plan enrollment, including shorter OEPs and the suspension of certain special enrollment periods ("SEPs"), such rules, the "Program Integrity Rules". Furthermore, on July 4, 2025, the President signed into law the One Big Beautiful Bill Act (the "OBBBA") which, among other relevant matters, limits the eligibility of APTCs for certain populations, and requires additional verification procedures to confirm member eligibility for APTCs. On August 22, 2025, in connection with City of Columbus vs. Kennedy, in which the plaintiffs alleged certain provisions of the Program Integrity Rules are contrary to law, a federal district court in Maryland issued a nationwide stay on several provisions of the Program Integrity Rules pending a final ruling on the merits of the case. The litigation did not conclude before 2026 and the stayed provisions were not in effect during the 2026 OEP, and it is unclear at this time whether the stay will be lifted during 2026. Provisions of the Program Integrity Rules unaffected by the stay became effective on August 25, 2025. On February 11, 2026, the U.S. Department of Health and Human Services ("HHS") published the proposed Notice of Benefit and Payment Parameters ("NBPP") for policy year 2027. The NBPP, which has not been made final as of the date of this filing, reintroduces updated versions of certain of the stayed provisions of the Program Integrity Rules, to be effective beginning in policy year 2027. For example, CMS has reintroduced stricter income verification rules, requiring individuals to submit documents to verify their income when data sources indicate household income is below 100% of the Federal Poverty Line ("FPL"), and removing the option for Health Insurance Marketplaces to accept income attestations from individuals when I.R.S. tax data is unavailable for the household. Furthermore, beginning in policy year 2027 for Health Insurance Marketplaces operated by the federal government and 2028 for Health Insurance Marketplaces operated by individual states, the marketplaces will be required to deem a tax filer ineligible for APTCs if the tax filer received APTCs in a prior year but failed to file a federal income tax return to reconcile their eligibility for the APTCs. We expect these provisions, if enacted, to impact enrollment processes and APTC eligibility during the 2027, as well as future, OEPs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We expect that the expiration of the eAPTCs, and the implementation of the Program Integrity Rules and the OBBBA could continue to negatively impact the size of the Health Insurance Marketplaces and our membership in future years. Any resulting market contraction could negatively impact market morbidity. For more information, see Part I, Item 1, *"Business–Government Regulation–Ongoing Requirements and Changes to the ACA", and Part I, Item 1A. "Risk Factors-Most Material Risks to Us-Our success and ability to grow our business depend in part on retaining and expanding our member base. If we fail to add new members or retain current members, or manage our membership growth appropriately to meet our business objectives, our business, revenue, operating results, and financial condition could be harmed,"* and *"Risk Factors–Most Material Risks to Us–Failure to accurately estimate our incurred medical expenses or overall market morbidity, or effectively manage our medical costs or related administrative costs could negatively affect our financial position, results of operations, and cash flows"* in our Annual Report on Form 10-K for the year ended December 31, 2025.

*Proposed Tariffs*

The Trump administration has indicated that new tariffs may be imposed on a variety of products relevant to our business, including certain pharmaceutical products and ingredients and medical devices and supplies imported into the United States. For example, on April 2, 2026, the Trump administration issued a proclamation under Section 232 of the Trade Expansion Act imposing 100% tariffs on patented pharmaceuticals and associated pharmaceutical ingredients, imported into the United States, which take effect on July 31, 2026 unless manufacturers agree to specific government drug pricing deals or commit to shifting production and research and development of patented pharmaceuticals and pharmaceutical ingredients domestically. While this action may pressure drug manufacturers to reduce list prices, there could also be a corresponding, or even disproportionate, decrease in the pharmaceutical rebates that we negotiate and typically receive. Since the expectation of these rebates is factored into our premium pricing strategy, a reduction in rebates that outpaces any decline in underlying drug costs could exert financial pressure, potentially leading to an adverse impact on our earnings from operations and an increase in our MLR.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

Beyond the direct drug pricing mechanism, the imposition of tariffs, coupled with the uncertainty surrounding their implementation and scope, could introduce volatility across our medical cost structure. Potential broad market impacts include, among other things, higher costs for medical providers and facilities, higher pharmaceutical prices, higher costs of medical devices, and supplies and shortages of certain medicines and medical supplies. Shortages in medicines and supplies may also impact the health of our members, which in turn may result in higher medical costs. The unprecedented nature of these types of tariffs, as well as uncertainty around their implementation, could impact our ability to accurately estimate and effectively manage the impact on our medical expenses, which in turn could adversely affect our results of operations and financial position.

For additional details, see Part I, Item 1A. *"Risk Factors-Most Material Risks to Us-Failure to accurately estimate our incurred medical expenses or overall market morbidity, or effectively manage our medical costs or related administrative costs could negatively affect our financial position, results of operations, and cash flows" and "Risk Factors-Risks Related to the Regulatory Framework That Governs Us-Changes in laws, regulations or rules relating to taxes or tariffs could adversely affect us"* in our Annual Report on Form 10-K for the year ended December 31, 2025.

***Members***

Our membership is measured as of a particular point in time. Membership may vary throughout the year due to disenrollments, SEP, and other market dynamics that are in effect. Member disenrollments typically result from voluntary termination by members, non-payment of premiums beyond the member's grace period, or removal by CMS for failure to meet program integrity requirements or in accordance with fraud, waste and abuse laws and regulations. In accordance with federal regulations, members receiving APTC subsidies are entitled to a 90-day grace period for the non-payment of premiums. For all other member enrollees, the grace period is typically 30 days, subject to specific state requirements. Market dynamics may include but are not limited to enhancements, extensions, reductions or eliminations of APTCs; other legislative or regulatory actions, such as recent Congressional and CMS initiatives to improve the integrity in the ACA eligibility and enrollment process and pre-enrollment verification procedures; Medicaid redeterminations; or other factors that may cause the overall market to grow or decline.

***Risk Adjustment***

The risk adjustment programs in the markets we serve are administered federally by CMS and are designed to mitigate the potential impact of adverse selection and provide stability for Health Insurance Entities. Under these programs, each plan is assigned a risk score based upon demographic information and current year claims information related to its members. The risk score is used to adjust plan revenue to reflect the relative risk of the plan's enrolled population. We reevaluate our risk adjustment transfer estimates as new information and market data becomes available, until we receive the final reporting from CMS in later periods, up to twelve months in arrears. The Company records a receivable or payable as an adjustment to its premium revenues to reflect the year-to-date impact of the risk adjustment based on its best estimate. For the three months ended March 31, 2026, risk adjustment transfer payables were approximately 24% of direct policy premium revenue, up 13% compared to the same period in 2025. The three months ended March 31, 2026, reflected lower claims per member with an assumption of higher offsetting risk adjustment payables, as compared to the three months ended March 31, 2025.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

Our risk transfer estimates are subject to a high degree of estimation and variability, and are affected by the relative risk of our members, and in the case of the ACA, that of other insurers. The data we rely upon to calculate these estimates includes data received from independent third parties. In addition, the data may be incomplete, can vary considerably from period to period, requires considerable judgment in interpretation, lacks context, and provides limited insight. Moreover, our risk transfer estimates are subject to change due to factors outside of our control, such as changes in legislation, regulations, regulatory enforcement, enrollment in government health plans, inflation, market size, market morbidity, the actions of our competitors, and other uncertainties. There is a higher degree of uncertainty associated with estimates of risk adjustment transfers earlier in the policy year or, in the case of SEP driven enrollment, throughout the policy year, resulting from the fact that risk scores are based on lagged claim data. There is additional uncertainty for both markets and blocks of business that experience outsized growth, compounded by the lack of credible experience data on the newly enrolling population, including SEP driven enrollees and new members moving from one government program to another. Furthermore, there is also uncertainty associated with changes in other carriers' operations, which may impact the ultimate degree of market-level risk. Actual risk adjustment calculations and transfers have in the past materially differed, and could materially differ in the future, from our assumptions.

***Claims Incurred***

Our medical expenses are impacted by unit costs and utilization, as well as seasonal effects on medical costs, as members pay their contractual claims portion of claims responsibility, meeting their deductibles and out-of-pocket maximums over the course of the policy year, which shift more costs to us in the second half of the year as we pay a higher proportion of covered claims costs. Our medical expenses are also impacted by the number of days and holidays in a given period. Our medical and pharmacy costs can also exhibit seasonality depending on selection effects or changes in the risk profile of our membership and the proportion of our membership that is new in the calendar year. The emergence of medical and pharmacy claims is influenced by the aforementioned drivers, and further mix shifts may continue to alter claims incurred patterns in future periods.

***Seasonality***

Our business is generally affected by the seasonal patterns of our member enrollment, medical expenses, and health plan mix shift and product design. SEP or other market dynamics that drive enrollment and/or mix changes throughout the year may impact the per member levels of premiums, claims, and/or risk adjustment transfers. Claims utilization and risk adjustment seasonality may be affected by new member enrollment levels and plan mix in 2026, as newer members tend to take time to engage with their benefits, and the shift to higher deductible plans could concentrate a higher portion of total costs to the second half of the year.

***Reinsurance***

We believe our reinsurance agreements help us achieve important goals for our business, including risk management and capital efficiency. Our reinsurance agreements are contracted under two different types of arrangements: quota share reinsurance contracts and excess of loss ("XOL") reinsurance contracts. In quota share reinsurance, the reinsurer agrees to assume a specified percentage of the ceding company's losses in exchange for a corresponding percentage of premiums. In XOL reinsurance, the reinsurer agrees to assume all or a portion of the ceding company's losses in excess of a specified amount. Under XOL reinsurance, the premium payable to the reinsurer is negotiated by the parties based on losses on an individual member in a given calendar year and their assessment of the amount of risk being ceded to the reinsurer. In the case of federal and state-run reinsurance programs, no reinsurance premiums are paid. The reinsurance agreements do not relieve us of our primary medical claims incurred obligations. Refer to *"Note 10 - Reinsurance"* included elsewhere in this Quarterly Report on Form 10-Q for a description of the accounting methods used to record our quota share reinsurance arrangements.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Critical Accounting Policies and Estimates**

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. A summary of the Company's significant accounting policies is included in *"Note 2 - Summary of Significant Accounting Policies,"* in our Annual Report on Form 10-K for the year ended December 31, 2025. Certain of our accounting policies are considered critical, as these policies require significant, difficult, or complex judgments by management, often requiring the use of estimates about the effects of matters that are inherently uncertain. As of March 31, 2026, there were no significant changes to our critical accounting estimates from what was reported in our Annual Report on Form 10-K for the year ended December 31, 2025.

**Components of Our Results of Operations**

***Premium***

Premium revenue includes premium subsidies received from the federal government, policy premiums collected directly from our members, and assumed policy premiums earned as part of the reinsurance arrangement under the Cigna+Oscar Small Group plan previously offered, net of risk adjustment transfers and ceded premium from reinsurance contracts accounted for under reinsurance accounting.

The Company receives a fixed premium per member per month and recognizes premium revenue during the period in which it is obligated to provide services to its members. For direct policy premiums, revenue is recognized based on membership and eligibility criteria provided by CMS and is subject to monthly retroactive adjustment. Premium revenue is recorded net of adjustment for premium expected to be returned to CMS as a result of expected member disenrollments. These adjustments typically result from non-payment of premiums or the removal of members by CMS in connection with program integrity requirements and fraud, waste and abuse laws and regulations.

The Company did not renew the Cigna+Oscar Small Group arrangement after the expiration of the initial term on December 31, 2024.

***Investment Income***

Investment income includes investment income, interest earned, and gains (losses) on our investment portfolio.

***Other Revenues***

Other revenues include revenue earned through our Marketplace Subsidiaries, fees for services performed via the +Oscar platform, revenue sharing from virtual credit card rebates, and sublease income.

***Medical***

Medical expense consists of both paid and unpaid medical expenses incurred to provide medical services and products to our members. Medical claims include fee-for-service claims, pharmacy benefits, capitation payments to providers, disputed provider claims, and various other medical-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Medical claims are recognized in the period healthcare services are provided. Unpaid medical expenses include claims reported and in the process of being settled, but that have not yet been paid, as well as healthcare costs incurred but not yet reported to us, which are collectively referred to as benefits payable or claim reserves. The development of the claim reserve estimate is based on actuarial methodologies that consider underlying claim payment patterns, medical cost inflation, historical developments, such as claim inventory levels and claim receipt patterns, and other relevant factors. The methods for making such estimates and for establishing the resulting liability are continuously reviewed and any adjustments are reflected in the period determined. Medical expense also reflects the net impact of our ceded reinsurance claims from reinsurance contracts accounted for under reinsurance accounting.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

***Selling, General, and Administrative Expenses***

Selling, general, and administrative expenses primarily include distribution and servicing costs, premium taxes, exchange fees, other taxes and fees, employee-related expenses, costs of software and hardware, stock-based compensation, the impact of quota share reinsurance, and other administrative costs.

***Other Expenses (Income)***

Other expenses (income) consists primarily of miscellaneous expenses or income that are not core to our operations, including profit sharing arrangements with our co-branded health plans and changes in the fair value of financial instruments.

***Income Tax Expense (Benefit)***

Income tax expense (benefit) consists of changes to our current and deferred federal and state tax assets and liabilities. Income taxes are recorded as deferred tax assets and deferred tax liabilities based on differences between the book and tax bases of assets and liabilities. Our deferred tax assets and liabilities are calculated by applying the current tax rates and laws to taxable years in which such differences are expected to reverse.

***Net income (loss) Attributable to Noncontrolling Interests***

Net income (loss) attributable to noncontrolling interests represents the share of the Company's earnings allocated to the Company's joint venture partner.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Results of Operations**

The following table sets forth our results of operations for the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands, except percentages) | **2026** | **2025** |
| **Revenue** |  |  |
| &nbsp;&nbsp;&nbsp;Premium | $4580862 | $2995821 |
| &nbsp;&nbsp;&nbsp;Investment income | 60614 | 46112 |
| &nbsp;&nbsp;&nbsp;Other revenues | 5718 | 4330 |
| **Total revenue** | **4647194** | **3046263** |
| **Operating Expenses** |  |  |
| &nbsp;&nbsp;&nbsp;Medical | 3229857 | 2259651 |
| &nbsp;&nbsp;&nbsp;Selling, general, and administrative | 706234 | 482759 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 7018 | 6730 |
| Total operating expenses | 3943109 | 2749140 |
| **Earnings from operations** | **704085** | **297123** |
| &nbsp;&nbsp;&nbsp;Interest expense | 5383 | 5994 |
| &nbsp;&nbsp;&nbsp;Other expenses (income) | (71) | 2918 |
| **Earnings before income taxes** | **698773** | **288211** |
| &nbsp;&nbsp;&nbsp;Income tax expense | 19750 | 12705 |
| **Net income** | **679023** | **275506** |
| &nbsp;&nbsp;&nbsp;Less: Net income attributable to noncontrolling interests | 27 | 235 |
| **Net income attributable to Oscar Health, Inc.** | $**678996** | $**275271** |
| MLR | 70.5% | 75.4% |
| SG&A expense ratio | 15.2% | 15.8% |

---

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

***Premium***

Premium revenue increased $1,585.0 million, or 53%, for the three months ended March 31, 2026, compared to the same period in 2025. This increase was driven by higher membership and premium rate increases, partially offset by an increase in the net risk adjustment transfer accrual. As of March 31, 2026, membership increased by 1.1 million, or 56% compared to March 31, 2025, primarily driven by above market growth during the 2026 OEP.

The following table summarizes the Company's membership by offering:

---

| | | |
|:---|:---|:---|
| | **As of March 31,** | **As of March 31,** |
| **Membership by Offering** | **2026** | **2025** |
| Individual and Small Group <sup>(1)</sup> | 3174489 | 2021484 |
| Cigna+Oscar <sup>(2)</sup> |  | 17983 |
| **Total Members** <sup>(3)</sup> | **3174489** | **2039467** |
| (1) 2025 membership includes small group members. The Company no longer offers small group plans effective December 15, 2024.  | (1) 2025 membership includes small group members. The Company no longer offers small group plans effective December 15, 2024.  | (1) 2025 membership includes small group members. The Company no longer offers small group plans effective December 15, 2024.  |
| (2) Represents total membership for our former co-branded partnership with Cigna. We did not renew the Cigna+Oscar Small Group arrangement after its initial term ended on December 31, 2024. | (2) Represents total membership for our former co-branded partnership with Cigna. We did not renew the Cigna+Oscar Small Group arrangement after its initial term ended on December 31, 2024. | (2) Represents total membership for our former co-branded partnership with Cigna. We did not renew the Cigna+Oscar Small Group arrangement after its initial term ended on December 31, 2024. |
| (3) Represents effectuated members. Effectuated members are those who are actively enrolled in one of our plans and whose required premium payments have either been made or are within the payment grace period. A member covered under more than one of our health plans counts as a single member for the purposes of this metric. | (3) Represents effectuated members. Effectuated members are those who are actively enrolled in one of our plans and whose required premium payments have either been made or are within the payment grace period. A member covered under more than one of our health plans counts as a single member for the purposes of this metric. | (3) Represents effectuated members. Effectuated members are those who are actively enrolled in one of our plans and whose required premium payments have either been made or are within the payment grace period. A member covered under more than one of our health plans counts as a single member for the purposes of this metric. |

---

***Investment Income***

Investment income increased $14.5 million, or 31%, for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to higher invested assets, offset by lower yield.

***Medical Expenses and MLR***

Medical expenses increased $970.2 million, or 43%, for the three months ended March 31, 2026, compared to the same period in 2025. This increase was primarily due to increased membership, partially offset by modestly lower medical cost trend. MLR decreased for the three months ended March 31, 2026, compared to the same period in 2025. The decrease was primarily due to our disciplined pricing strategy, claims and risk adjustment seasonality from metal and new member mix, and favorable prior period reserve development.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| (in thousands, except percentages) | **2026** | **2025** |
| Net claims before ceded quota share reinsurance <sup>(A)</sup> | $3229857 | $2259651 |
| Net premiums before ceded quota share reinsurance <sup>(B)</sup> | $4580862 | $2995821 |
| Medical Loss Ratio <sup>(A divided by B)</sup> | 70.5% | 75.4% |

---

***Selling, General, and Administrative Expenses and SG&A Expense Ratio***

Selling, general, and administrative expenses increased $223.5 million, or 46%, for the three months ended March 31, 2026, compared to the same period in 2025. This increase was driven by higher membership year over year, resulting in higher volume-driven costs such as taxes and fees and broker commissions. The SG&A expense ratio decreased 60 basis points to 15.2% for the three months ended March 31, 2026, compared to 15.8% for the same period in 2025. The decrease was primarily due to greater fixed cost leverage and disciplined cost management, partially offset by the impact of higher risk adjustment as a percentage of premium.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Liquidity and Capital Resources**

***Overview***

We maintain liquidity at two levels of our corporate structure, through our health insurance and Health Maintenance Organization subsidiaries (collectively, "Health Insurance Subsidiaries") and through our parent company, Oscar Health, Inc. (on a standalone basis "Parent"), together with subsidiaries excluding our Health Insurance Subsidiaries. The majority of our assets consist of cash and cash equivalents and investments.

As of March 31, 2026 and December 31, 2025, total cash and cash equivalents and investments held by our Health Insurance Subsidiaries was $7.8 billion and $5.1 billion, respectively, of which $19.1 million and $18.3 million, respectively, was on deposit with regulators as required for statutory licensing purposes. These amounts are classified as restricted deposits on the balance sheets. As of March 31, 2026 and December 31, 2025, total cash and cash equivalents and investments held by our entities other than the Health Insurance Subsidiaries were $279.2 million and $414.2 million, respectively, of which $9.6 million and $14.7 million was restricted as of March 31, 2026 and December 31, 2025, respectively.

Our Health Insurance Subsidiaries' states of domicile have statutory minimum capital requirements that are intended to measure capital adequacy, taking into account the risk characteristics of an insurer's investments and products. The combined statutory capital and surplus of our Health Insurance Subsidiaries was estimated to be approximately $1.7 billion and $1.0 billion as of March 31, 2026 and December 31, 2025, respectively, which was in compliance with and in excess of the minimum capital requirements for each period. The Health Insurance Subsidiaries in aggregate exceeded the minimum statutory risk-based capital ("RBC") requirement by $356 million as of December 31, 2025 and are estimated to have approximately $809 million of excess capital as of March 31, 2026. The Health Insurance Subsidiaries may be subject to additional capital and surplus requirements in the future, as a result of factors such as increasing membership and medical costs or changes in risk adjustment transfer estimates, which the Parent would be required to fund to the extent the applicable Health Insurance Subsidiary did not have excess capital to cover the requirement. In such circumstances we may need to incur additional indebtedness, sell capital stock, or access other sources of funding in order to fund such requirements. During periods of increased volatility, adverse securities and credit markets, including those due to rising interest rates, may exert downward pressure on the availability of liquidity and credit capacity for certain issuers, and any such funding may not be available on favorable terms, or at all.

As certain of our Health Insurance Subsidiaries have become profitable and to the extent their levels of statutory capital and surplus exceed applicable minimum regulatory requirements, we may make periodic requests for dividends and distributions from our subsidiaries to fund our operations or seek to enter into transactions or structures that enable us to efficiently deploy this excess capital, which may or may not require approval by our regulators. During the three months ended March 31, 2026, the Parent received approximately $300.0 million in capital distributions from the Health Insurance Subsidiaries. As noted below, these funds were subsequently used to fund a new insurance subsidiary, Oscar Health Maintenance Organization of Florida, Inc. During the three months ended March 31, 2025, the Health Insurance Subsidiaries did not make any loan repayments or capital distributions to the Parent.

During the three months ended March 31, 2026, Parent made $425.5 million of capital contributions to the Health Insurance Subsidiaries, including $300 million in funding for a new insurance subsidiary, Oscar Health Maintenance Organization of Florida, Inc. During the three months ended March 31, 2025, Parent made no capital contributions to the Health Insurance Subsidiaries. Our Health Insurance Subsidiaries also utilize quota share reinsurance arrangements to reduce our minimum capital and surplus requirements, which are designed to enable us to efficiently deploy capital to fund our growth. We estimate that had we not had any quota share reinsurance arrangements in place, the Health Insurance Subsidiaries would have been required to hold approximately $1,081.7 million and $683.1 million of additional capital as of March 31, 2026 and December 31, 2025, respectively, which the Parent would have been required to fund to the extent the applicable Health Insurance Subsidiary did not have excess capital to cover the requirement.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

***Short-Term Cash Requirements***

The Company's cash requirements within the next twelve months include benefits payable, risk adjustment transfer payables, current lease liabilities, interest payable on debt, other current liabilities, and other obligations. We expect the cash required to meet these obligations to be primarily funded by cash available for general corporate use, cash flows from current operations, and/or the realization of current assets, such as accounts receivable. Based on our current forecast, we believe the Company's cash, cash equivalents, and investments, not including restricted cash, will be sufficient to fund our operating requirements for at least the next twelve months.

***Long-Term Cash Requirements***

Our long-term cash requirements under our various contractual obligations and commitments include operating leases. We expect the cash required to meet our long-term obligations to be primarily generated through future cash flows from operations. See *"Note 13 - Leases"* in our Annual Report on Form 10-K for the year ended December 31, 2025 for further detail of our obligations and the timing of expected future payments.

***2031 Convertible Senior Notes***

In February 2022, the Company issued $305.0 million in aggregate principal amount of convertible senior notes due 2031 (the "2031 Notes") in a private placement to funds affiliated with or advised by Dragoneer Investment Group, LLC, Thrive Capital, LionTree Investment Management, LLC, and Tenere Capital LLC (the "Initial Purchasers"). In connection with the sale and issuance of the 2031 Notes, on January 27, 2022, we entered into an investment agreement with the Initial Purchasers (the "Investment Agreement") and on February 3, 2022, we entered into an indenture with U.S. Bank, as Trustee (the "2031 Indenture").

The 2031 Notes bear interest at a rate of 7.25% per annum, payable in cash, semi-annually in arrears on June 30 and December 31 of each year, commencing on June 30, 2022. The 2031 Notes will mature on December 31, 2031, subject to earlier repurchase, redemption, or conversion, as further discussed in "*Note 9 - Debt,*" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. As of March 31, 2026, $35 million aggregate principal amount of the 2031 Notes remained outstanding.

For more information on our 2031 Notes, including details relating to repurchase, redemption and conversions of the 2031 Notes, see *"Part II, Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—2031 Convertible Senior Notes"* and *"Note 9 - Debt"* to our Consolidated Financial Statements, each in our Annual Report on Form 10-K for the year ended December 31, 2025, and, *"Note 9 – Debt"* to our Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.

***2030 Convertible Senior Notes***

On September 18, 2025, the Company issued $410.0 million aggregate principal amount of convertible senior notes due 2030 (the "2030 Notes"). The 2030 Notes were issued pursuant to an indenture (the "2030 Indenture"), dated as of September 18, 2025, between the Company and U.S. Bank Trust Company, National Association, as trustee.

The 2030 Notes will accrue interest at a rate of 2.25% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2026. The 2030 Notes will mature on September 1, 2030, unless they are earlier repurchased, redeemed, or converted, as further discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

On September 15, 2025, in connection with the pricing of the offering of 2030 Notes, the Company entered into privately negotiated capped call transactions (the "Base Capped Call Transactions") with certain of the 2030 Notes initial purchasers or their affiliates and certain other financial institutions (the "Option Counterparties"). In addition, on September 16, 2025, in connection with the initial purchasers' exercise of their option to purchase additional 2030 Notes, the Company entered into additional capped call transactions (the "Additional Capped Call Transactions," and, together with the Base Capped Call Transactions, (the "Capped Call Transactions") with each of the Option Counterparties. The Capped Call Transactions cover the aggregate number of shares of the Company's Class A common stock that initially underlie the 2030 Notes (subject to customary anti-dilution adjustments), and are expected to reduce potential dilution to the Company's Class A common stock upon any conversion of 2030 Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted 2030 Notes, with such reduction and/or offset subject to a cap, based on the cap price of the Capped Call Transactions.

As discussed above under *"–2031 Convertible Senior Notes"*, the 2030 Notes were originally subordinated to the 2031 Notes. In connection with the Exchange Agreement and the related transactions, as of November 5, 2025, the 2030 Notes ceased to be subordinated to the 2031 Notes.

For more information on our 2030 Notes, including details relating to repurchase, redemption and conversions of the 2030 Notes, and the Capped Call Transactions, see *"Part II, Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—2030 Convertible Senior Notes"* and *"Note 9 - Debt"* to our Consolidated Financial Statements, each in our Annual Report on Form 10-K for the year ended December 31, 2025, and "*Note 9 – Debt*" to our Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.

***Revolving Credit Facility***

On February 6, 2026, we entered into a $475.0 million secured three-year revolving credit facility (the "2026 Revolving Credit Facility"), pursuant to a Credit Agreement (the "2026 Credit Agreement") by and among the Company, certain subsidiaries of the Company, as subsidiary guarantors, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto. For more information, see "*Note 9 – Debt*" to our Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.

***Investments***

We generally invest our cash in U.S. Treasury instruments, federal and state agency securities, investment grade corporate bonds, and asset backed securities to improve our overall investment return. These investments are purchased pursuant to board of directors ("Board") approved investment policies that conform to applicable state laws and regulations.

Our investment policies are designed to provide liquidity, preserve capital, and optimize the total return on invested assets. These policies also align with the constraints of state regulations governing the types of investments our subsidiaries can hold. These investment policies require that our investments in U.S. corporate bonds and asset backed securities have final maturities of no more than five years from the date of issuance and U.S. federal and state government obligations have final maturities of no more than seven years from the settlement date. Professional portfolio managers operating under documented guidelines manage our investments and a portion of our cash equivalents. Our portfolio managers are directed to obtain our prior approval before selling investments in a loss position.

Net investment income on a consolidated basis was $60.6 million and $46.1 million for the three months ended March 31, 2026 and 2025, respectively. Net investment income for our Health Insurance Subsidiaries was $57.2 million and $44.4 million for the three months ended March 31, 2026 and March 31, 2025, respectively.

Our restricted investments consist primarily of cash and cash equivalents and U.S. Treasury securities; we have the ability to hold such restricted investments until maturity. The Company maintains cash and cash equivalents and investments on deposit or pledged to various state agencies as a condition for licensure. We classify our restricted deposits as long-term given the requirement to maintain such assets on deposit with regulators.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

***Summary of Cash Flows***

Our cash flows used in operations may differ substantially from our net income (loss) due to non-cash charges or due to changes in balance sheet accounts.

The timing of our cash flows from operating activities can also vary among periods due to the timing of payments made or received. Some of our payments and receipts, including loss settlements, rebates from our pharmacy benefit manager, risk adjustment transfers, and subsequent reinsurance receipts, can be significant. Therefore, their timing can influence cash flows from operating activities in any given period. The potential for a large claim under an insurance or reinsurance contract means that our Health Insurance Subsidiaries may need to make substantial payments within relatively short periods of time, which would have a negative impact on our operating cash flows.

Our primary operating cash flow sources are premiums and investment income. Our primary operating cash flow uses are payments for claims, risk adjustment transfers, and operating expenses, including interest expense. For the three months ended March 31, 2026, net cash provided by operating activities was $2.6 billion as compared with $0.9 billion for the same period in 2025. The increase was primarily due to higher premiums received, partially offset by higher claim disbursements.

Cash flows from investing activities primarily include the purchase and disposition of financial instruments. For the three months ended March 31, 2026, net cash used in investing activities was $590.3 million as compared to net cash used in investing activities of $174.2 million for the same period in 2025. This increase was primarily driven by higher investment purchases.

Cash flows from financing activities may include proceeds from the issuance of debt securities, proceeds from stock option exercises, and tax payments related to the net settlement of share-based awards. For the three months ended March 31, 2026, net cash used in financing activities was $3.6 million as compared to net cash provided of $4.9 million for the same period in 2025. The change was primarily due to new debt issuance costs and lower proceeds from stock option exercises.

 **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in interest rates and/or inflation and the resulting impact on investment income and interest expense. We do not hold financial instruments for trading purposes.

***Interest Rate Risk***

We are subject to interest rate risk in connection with the fair value of our investment portfolio, which consists of U.S. Treasury and agency securities, corporate notes, asset-backed securities, and certificates of deposit. Our primary market risk exposure is driven by changes to prime rate based interest rates. Interest rate risk is highly sensitive due to many factors, including U.S. monetary and tax policies, U.S. and international economic factors, and other factors beyond our control. Assuming a hypothetical and immediate 1% increase in interest rates on March 31, 2026, the fair value of our investments would decrease by approximately $39 million. Any declines in interest rates over time would reduce our investment income.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e)

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2026, our disclosure controls and procedures were effective at the reasonable assurance level.

**Changes in Internal Control over Financial Reporting**

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2026 that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**PART II — OTHER INFORMATION**

**Item 1. Legal Proceedings**

The information required under this Part II, Item 1 is set forth in *"Note 12 - Commitments and Contingencies"* to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.

Given that such proceedings are subject to uncertainty, there can be no assurance that such legal proceedings, either individually or in the aggregate, will not have a material adverse effect on our business, results of operations, financial condition or cash flows.

**Item 1A. Risk Factors**

The risks that we believe are material to our investors are disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2025.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

On April 3, 2026 (the "Purchase Date"), the Company entered into a Stock Purchase Agreement with Mark T. Bertolini, the Company's Chief Executive Officer, pursuant to which the Company sold an aggregate of 1,000,000 shares of the Company's Class A common stock (the "Shares") to Mr. Bertolini for an aggregate purchase price of $11.9 million, at a price per share of $11.92, representing the per share closing price of the Company's Class A common stock as reported by the NYSE on the trading date immediately preceding the Purchase Date. No underwriting discounts or commissions were paid in connection with the transaction. The Shares were offered and sold in reliance upon the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction not involving a public offering.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

(a) None.

(b) None.

(c) On February 12, 2026, R. Scott Blackley, the Company's Chief Financial Officer, entered into a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c). Mr. Blackley's plan is for the sale of up to 210,000 shares of Class A common stock through June 26, 2027. The plan terminates on the earlier of the date all the shares under the plan are sold and June 26, 2027. No trades will commence under the plan until after the expiration of the applicable cooling off period on May 14, 2026.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

On March 24, 2026, Mario Schlosser, the Company's Co-Founder and Chief Technology Officer, entered into a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c). Mr. Schlosser's plan is for the exercise of vested stock options and the associated sale of up to 660,000 shares of Class B common stock, and the additional sale of up to 415,000 shares of Class B common stock, through June 30, 2027. The plan terminates on the earlier of the date all the shares under the plan are sold and June 30, 2027. No trades will commence under the plan until after the expiration of the applicable cooling off period on June 23, 2026.

As previously disclosed, on November 10, 2025, Mark T. Bertolini, the Company's Chief Executive Officer, in accordance with the Company's standard practice for employees and executive officers, entered into the Company's form of sell-to-cover instruction that is intended to satisfy the affirmative defense of Rule 10b5-1(c), providing for sales of a number of shares of Class A common stock as is necessary to cover tax withholding obligations incurred in connection with the vesting or settlement of restricted stock units held by Mr. Bertolini. On March 24, 2026, Mr. Bertolini amended and restated the existing instruction to exclude the settlement of certain shares of Class A common stock from the instruction. The amended and restated instruction will remain in effect so long as Mr. Bertolini is subject to such tax obligations, unless earlier terminated. The total number of shares of Class A common stock that may be sold pursuant to the amended and restated instruction is not determinable.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**Item 6. Exhibits**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed/<br>Furnished <br>Herewith** |
|<br>**Exhibit <br>Number** |<br>**Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing <br>Date** | **Filed/<br>Furnished <br>Herewith** |
| 3.1 | <u>[Amended and Restated Certificate of Incorporation of Oscar Health, Inc.](https://www.sec.gov/Archives/edgar/data/1568651/000119312521071893/d82779dex31.htm)</u> | 8-K | 001-40154 | 3.1 | 3/8/2021 |  |
| 3.2 | <u>[Amended and Restated Bylaws of Oscar Health, Inc.](https://www.sec.gov/Archives/edgar/data/1568651/000119312521071893/d82779dex32.htm)</u> | 8-K | 001-40154 | 3.2 | 3/8/2021 |  |
| 4.1 | <u>[Specimen Common Stock Certificate of Oscar Health, Inc.](https://www.sec.gov/Archives/edgar/data/1568651/000119312521049832/d28906dex41.htm)</u> | S-1/A | 333-252809 | 4.1 | 2/22/2021 |  |
| 10.1† | <u>[2026 Form of Performance Restricted Stock Unit Award Agreement under 2021 Incentive Award Plan](a1012026formofperformanc.htm)</u> |  |  |  |  | \* |
| 10.2† | <u>[Performance Restricted Stock Unit Award Agreement under 2021 Incentive Award Plan, by and between Oscar Health, Inc. and Mark T. Bertolini](a102performancerestricte.htm)</u> |  |  |  |  | \* |
| 10.3† | <u>[Restricted Stock Unit Award Agreement under 2021 Incentive Award Plan, by and between Oscar Health, Inc. and Mark T. Bertolini](a103restrictedstockunita.htm)</u> |  |  |  |  | \* |
| 10.4 | <u>[Credit Agreement, dated as of February 6, 2026, by and among Oscar Health, Inc., as borrower, certain subsidiaries of the Company, as subsidiary guarantors, JPMorgan Chase Bank, N.A., as administrative agent, and the several lenders party thereto](https://www.sec.gov/Archives/edgar/data/1568651/000156865126000008/oscar-revolvingcreditagr.htm)</u> | 8-K | 001-40154 | 10.1 | 2/10/2026 |  |
| 31.1 | <u>[Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.](a1q26oscrex311.htm)</u> |  |  |  |  | \* |
| 31.2 | <u>[Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.](a1q26oscrex312.htm)</u> |  |  |  |  | \* |
| 32.1 | <u>[Section 1350 Certification of Chief Executive Officer.](a1q26oscrex321.htm)</u> |  |  |  |  | \*\* |
| 32.2 | <u>[Section 1350 Certification of Chief Financial Officer.](a1q26oscrex322.htm)</u> |  |  |  |  | \*\* |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document |  |  |  |  | \* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  | \* |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  | \* |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  | \* |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  |  | \* |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  | \* |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101) |  |  |  |  | \* |

---

\*&nbsp;&nbsp;&nbsp;&nbsp;Filed herewith.

\*\*&nbsp;&nbsp;&nbsp;&nbsp;Furnished herewith.

† Indicates management contract or compensatory plan.

------

<u>[**Table of Contents**](#ic0ed02a1d98540d0b02bc707fdf6e276_10)</u>

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | OSCAR HEALTH, INC. | OSCAR HEALTH, INC. |
| Date: **May 7, 2026** | By: | /s/ Mark T. Bertolini |
|  |  | **Mark T. Bertolini** |
|  |  | **Chief Executive Officer** |
|  |  | (Principal Executive Officer) |
| Date: **May 7, 2026** | By: | /s/ R. Scott Blackley |
|  |  | **R. Scott Blackley** |
|  |  | **Chief Financial Officer** |
|  |  | (Principal Financial Officer) |
| Date: **May 7, 2026** | By: | /s/ Victoria Baltrus |
|  |  | **Victoria Baltrus** |
|  |  | **Chief Accounting Officer** |
|  |  | (Principal Accounting Officer) |

---

## Exhibit 10.1

![](a1012026formofperformanc001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;OSCAR HEALTH, INC. 2021 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Oscar Health, Inc., a Delaware corporation (the "Company"), has granted to the participant listed below ("Participant") the Performance Restricted Stock Units (the "PSUs") described in this Performance Restricted Stock Unit Grant Notice (this "Grant Notice"), subject to the terms and conditions of the Oscar Health, Inc. 2021 Incentive Award Plan (as amended from time to time, the "Plan") and the Performance Restricted Stock Unit Agreement attached hereto as Exhibit A, the Earned PSUs attached as Exhibit B and the Peer Group Companies attached as Exhibit C (Exhibits A, B and C together, the "Agreement"), all of which are incorporated into this Grant Notice by reference. Capitalized terms not specifically defined in this Grant Notice or the Agreement have the meanings given to them in the Plan. Participant: [To be specified] Grant Date: [______], 2026 Target Number of PSUs: [To be specified] Expiration Date: [______],[______] Vesting Schedule: The PSUs shall become earned and vest as described in Article II of the Agreement and Exhibit B. By accepting (whether in writing, electronically or otherwise) the PSUs, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. OSCAR HEALTH, INC. PARTICIPANT By: Name: [Participant Name] Title:

------

![](a1012026formofperformanc002.jpg)

Exhibit A PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT WHEREAS, in connection with the Company's grant of the PSUs to Participant, the parties desire to enter into this Performance Restricted Stock Unit Agreement (this "Agreement"); and NOW, THEREFORE, the Company and Participant hereby agree as follows: ARTICLE I. GENERAL I.1 Award of PSUs. The Company has granted the PSUs to Participant effective as of the Grant Date set forth in the Grant Notice (the "Grant Date"). Each PSU represents the right to receive one Share as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time (if ever) the PSUs have vested. I.2 Incorporation of Terms of Plan. The PSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. I.3 Unsecured Promise. The PSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company's general assets. I.4 Defined Terms. Capitalized terms not specifically defined in this Agreement shall have the meanings specified in the Grant Notice, Exhibit B or, if not defined in the Grant Notice or Exhibit B, in the Plan. In addition, the following defined terms shall apply: (a) "Assumed" shall mean that an Assumption occurs with respect to the Award in connection with a Change in Control. (b) "Cause" shall have such meaning as is contained in Participant's Employment Agreement or, if not defined therein, shall mean a determination by the Company of (i) Participant's unauthorized use or disclosure of the Company's confidential information or trade secrets; (ii) Participant's breach of any agreement between Participant and the Company; (iii) Participant's failure to comply with the Company's written policies or rules; (iv) Participant's conviction of, or plea of "guilty" or "no contest" to, a felony under the laws of the United States or any State thereof; (v) Participant's gross negligence or willful misconduct; (vi) Participant's continuing failure to perform assigned duties after receiving notification of such failure from the Company; or (vii) Participant's failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers, or employees. (c) "Change in Control Period" shall mean the twelve (12) month period beginning on the date on which a Change in Control occurs. (d) "Employment Agreement" shall mean any employment agreement, offer letter or similar written agreement between Participant and the Company or any of its affiliates. (e) "Good Reason" shall have the meaning ascribed to such term (or similar term) in Participant's Employment Agreement, if applicable. (f) "Qualifying Termination" shall mean Participant's Termination of Service (i) by the Company without Cause or (ii) if Participant's Employment Agreement contains a definition of "Good Reason" (or similar term), by Participant for Good Reason. 1

------

![](a1012026formofperformanc003.jpg)

(g) "Restrictive Covenants" shall mean any confidentiality, intellectual property assignment, non-competition, non-solicitation, non-disparagement and other protective covenants contained in any written agreement between the Company (or an affiliate) and Participant. (h) "Retirement" shall mean a Termination of Service due to retirement (as determined by the Company in its sole discretion) if such Termination of Service (i) occurs on or after the completion by Participant of five years of service with the Company (which need not be continuous) and (ii) the Participant's age equals or exceeds 55 (in each case measured in years, rounded down to the nearest whole number). (i) "Retirement Acceleration Period" means a number of years following Participant's Retirement that is equal to (i) Participant's number of years of service as an Employee (rounded down to the nearest whole number), divided by (ii) five (with such quotient rounded down to the nearest whole number). ARTICLE II. VESTING; FORFEITURE AND SETTLEMENT II.1 Earned PSUs; General Vesting. The PSUs will be earned as set forth on Exhibit B attached hereto. Subject to Section 2.2, any Earned PSUs (as defined in Exhibit B) will vest on the Expiration Date, subject to Participant's continued service as a Service Provider through the Expiration Date. Any PSUs that remain outstanding and unvested as of immediately following the Expiration Date (including as a result of failing to become Earned PSUs) will be forfeited and terminated (for no consideration) as of the Expiration Date. II.2 Change in Control; Termination of Service. (a) Change in Control. (i) If a Change in Control occurs and Participant remains in continued service as a Service Provider until at least immediately prior to such Change in Control, then, effective as of the date of such Change in Control: (x) the PSUs shall become Earned PSUs in accordance with Exhibit B, and (y) (A) to the extent the Award is Assumed in connection with such Change in Control, any such Earned PSUs will convert into a time-vesting Restricted Stock Unit ("RSU") award that, following such Change in Control, will remain outstanding and eligible to vest on the Expiration Date, subject to Participant's continued Service as a Service Provider through the Expiration Date; or (B) to the extent the Award is not Assumed in connection with such Change in Control, 100% of any such Earned PSUs will vest as of immediately prior to such Change in Control. (ii) If Participant experiences (A) a Termination of Service due to death or Disability following a Change in Control or (B) a Qualifying Termination following a Change in Control that does not occur during the Change in Control Period, then, in either case, a number of RSUs subject to such time-vesting RSU award shall vest as of the date of Participant's Termination of Service equal to the number of RSUs multiplied by a fraction, (x) the numerator of which is the number of days Participant was in service from the first day of the Performance Period through the date of Participant's Termination of Service and (y) the denominator of which is the number of days from (and including) the first day of the Performance Period through (and including) the Expiration Date. 2

------

![](a1012026formofperformanc004.jpg)

(iii) If Participant experiences a Qualifying Termination during the Change in Control Period, then 100% of the RSUs subject to such time-vesting RSU award shall vest as of the date of Participant's Termination of Service. (iv) Upon Participant's Retirement following a Change in Control, then a number of RSUs subject to such time-vesting RSU award shall vest as of the date of Participant's Termination of Service equal to the number of RSUs multiplied by a fraction, (x) the numerator of which is the sum of (A) the number of days Participant was in service from the first day of the Performance Period through the date of Participant's Termination of Service and (B) the number of days in the Retirement Acceleration Period and (y) the denominator of which is the number of days from (and including) the first day of the Performance Period through (and including) the Expiration Date. Any RSUs that do not become vested in accordance with the foregoing automatically will be forfeited and terminated as of the date of Participant's Termination of Service without consideration therefor. (b) Termination due to Death or Disability (pre-Change in Control). Upon Participant's Termination of Service due to death or Disability, (i) the PSUs shall remain outstanding and eligible to become Earned PSUs in accordance with Exhibit B and (ii) a number of Earned PSUs shall vest in accordance with the following sentence as of the earlier of the Expiration Date or a Change in Control. The number of Earned PSUs that shall be eligible to vest shall equal to the number of Earned PSUs determined in accordance with Exhibit B, multiplied by a fraction, (x) the numerator of which is the number of days Participant was in service from the first day of the Performance Period through the date of Participant's Termination of Service and (y) the denominator of which is the number of days from (and including) the first day of the Performance Period through (and including) the Expiration Date. Any Earned PSUs that do not become vested in accordance with the foregoing automatically will be forfeited and terminated as of the last day of the Performance Period without consideration therefor. (c) Termination due to Retirement (pre-Change in Control). Upon Participant's Retirement, (i) the PSUs shall remain outstanding and eligible to become Earned PSUs in accordance with Exhibit B and (ii) a number of Earned PSUs shall vest in accordance with the following sentence as of the earlier of the Expiration Date or a Change in Control. The number of Earned PSUs that shall be eligible to vest shall equal the number of Earned PSUs determined in accordance with Exhibit B, multiplied by a fraction, (x) the numerator of which is the sum of (A) the number of days Participant was in service from the first day of the Performance Period through the date of Participant's Termination of Service and (B) the number of days in the Retirement Acceleration Period and (y) the denominator of which is the number of days from (and including) the first day of the Performance Period through (and including) the Expiration Date. Any Earned PSUs that do not become vested in accordance with the foregoing automatically will be forfeited and terminated as of the last day of the Performance Period without consideration therefor. (d) Other Terminations. If Participant experiences a Termination of Service for any reason other those set forth in Sections 2.2(a)-(c), all PSUs (or, to the extent applicable, RSUs) that have not become vested on or prior to the date of such Termination of Service automatically will be forfeited and terminated as of the termination date without consideration therefor. (e) Release; Restrictive Covenants. The accelerated vesting set forth in Sections 2.2(a)-(c) is subject to and conditioned upon (i) Participant's (or Participant's estate's) execution, delivery and non-revocation of a general release of claims in a form prescribed by the Company within 30 days (or, to the extent required by law, 52 days) following the date of Participant's Termination of Service and (ii) Participant's continued compliance with the Restrictive Covenants. 3

------

![](a1012026formofperformanc005.jpg)

II.3 Settlement. (a) The PSUs (or, to the extent applicable, RSUs) will be paid in Shares as soon as administratively practicable following the applicable vesting date, but in no event later than March 15 of the year following the year in which such vesting date occurs. (b) Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)); provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A. ARTICLE III. TAXATION AND TAX WITHHOLDING III.1 Representation. Participant represents to the Company that Participant has reviewed with Participant's own tax advisors the tax consequences of this award of PSUs (the "Award") and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. III.2 Tax Withholding. (a) Subject to Section 3.2(b), payment of the withholding tax obligations with respect to the Award may be by any of the following, or a combination thereof, as determined by the Participant or the Administrator: (i) Cash or check; (ii) In whole or in part by delivery of Shares, including Shares delivered by attestation and Shares retained from the Award creating the tax obligation, valued at their Fair Market Value on the date of delivery; or (iii) In whole or in part by the Company withholding of Shares otherwise vesting or issuable under this Award in satisfaction of any applicable withholding tax obligations. (b) Unless Participant or the Administrator otherwise determines, and subject to Section 10.17 of the Plan, payment of the withholding tax obligations with respect to the Award shall be by delivery (including electronically or telephonically to the extent permitted by the Company) by Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company that Participant has placed a market sell order with such broker with respect to Shares then-issuable upon settlement of the Award, and that the broker has been directed to deliver promptly to the Company funds sufficient to satisfy the applicable tax withholding obligations; provided, that payment of such proceeds is then made to the Company at such time as may be required by the Administrator. (c) Subject to Section 9.5 of the Plan, the applicable tax withholding obligation will be determined based on Participant's Applicable Withholding Rate. Participant's "Applicable Withholding Rate" shall mean (i) if Participant is subject to Section 16 of the Exchange Act, the greater of (A) the minimum applicable statutory tax withholding rate or (B) with Participant's consent, the maximum individual tax withholding rate permitted under the rules of the applicable taxing authority for tax withholding attributable to the underlying transaction, or (ii) if Participant is not subject to Section 16 4

------

![](a1012026formofperformanc006.jpg)

of the Exchange Act, the minimum applicable statutory tax withholding rate or such other higher rate approved by the Company; provided, however, that (i) in no event shall Participant's Applicable Withholding Rate exceed the maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America); and (ii) the number of Shares tendered or withheld, if applicable, shall be rounded up to the nearest whole Share sufficient to cover the applicable tax withholding obligation, to the extent rounding up to the nearest whole Share does not result in the liability classification of the PSUs under generally accepted accounting principles. (d) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the PSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the PSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the PSUs or the subsequent sale of Shares. The Company and its Subsidiaries do not commit and are under no obligation to structure the PSUs to reduce or eliminate Participant's tax liability. ARTICLE IV. OTHER PROVISIONS IV.1 Adjustments. Participant acknowledges that the PSUs and the Shares subject to the PSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. In addition, the Relative TSR performance metrics and the Absolute TSR Cap (each, as defined in Exhibit B) are based upon, among other things, (i) certain assumptions about the future business of the Company, (ii) a management model prepared by the Company for the projected business of the Company and its Affiliates and (iii) the continued application of accounting policies used by the Company as of the Grant Date. Accordingly, in the event that, after such date, the Administrator determines that (i) any dividend or other distribution (whether in the form of cash, common stock, other securities, or other property), (ii) any unusual or nonrecurring transactions or events (including the occurrence of a regulatory event) affecting the Company or the financial statements of the Company, (iii) any changes in Applicable Laws, or (iv) any changes in generally accepted accounting principles applicable to, or the accounting policies used by, the Company occur, such that an adjustment is determined by the Administrator to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available with respect to the Award, then the Administrator shall in good faith and in such manner as it may deem equitable, adjust the applicable Relative TSR Ranking and/or Relative TSR Earned Percentage with respect to Relative TSR performance and the Absolute TSR Cap with respect to TSR performance, in any case, to reflect the effect or projected effect of such transaction(s) or event(s) on such performance levels. IV.2 Clawback. The Award and the Shares issuable hereunder shall be subject to any clawback or recoupment policy in effect on the Grant Date or as may be adopted or maintained by the Company following the Grant Date, including the Company's Policy for Recovery of Erroneously Awarded Compensation. IV.3 Notices. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company's Chief Legal Officer at the Company's principal office or the Chief Legal Officer's then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the Designated Beneficiary) at Participant's last known mailing address, email address or facsimile number in the Company's personnel files. By a notice 5

------

![](a1012026formofperformanc007.jpg)

given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation. IV.4 Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. IV.5 Conformity to Securities Laws. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws. IV.6 Successors and Assigns. The Company may assign any of its rights under this Agreement to a single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in this Agreement or the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. IV.7 Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the PSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. IV.8 Entire Agreement; Amendment. The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator or the Board; provided, however, that except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall materially and adversely affect the PSUs without the prior written consent of Participant. IV.9 Agreement Severable. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. IV.10 Limitation on Participant's Rights. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the PSUs, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the PSUs, as and when settled pursuant to the terms of this Agreement. IV.11 Not a Contract of Employment. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary 6

------

![](a1012026formofperformanc008.jpg)

or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. IV.12 Counterparts. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. \* \* \* \* \* 7

------

![](a1012026formofperformanc009.jpg)

Exhibit B EARNED PSUS The number of PSUs that will become earned as of the completion of the Performance Period (such PSUs, the "Earned PSUs") shall be determined as set forth in this Exhibit B. Any Earned PSUs shall vest as set forth in Article II of the Agreement. Earned PSUs (General) The number of Earned PSUs shall be determined by multiplying the Target Number of PSUs set forth in the Grant Notice by the applicable Relative TSR Earned Percentage, as determined in accordance with the following table, provided, however, that if the Company's TSR (as defined below) for the Performance Period is less than 0%, then the Relative TSR Earned Percentage shall be equal to the lesser of 100% and the percentage determined in accordance with the table below (the "Absolute TSR Cap"): Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 175% 3 175% 4 150% 5 125% 6 100% 7 75% 8 50% 9 25% 10 25% 11 0% 12 0% In the event that the Company and one or more Peer Group Companies achieve the same TSR, then all tied companies will be deemed to have achieved the same relative TSR ranking that falls below the next higher performing Peer Group Company, if any. For example, if both the Company and a Peer Group Company achieve the same, highest TSR among the Peer Group, then both the Company and such Peer Group Company will be deemed to have earned the #1 ranking. In the event that one or more Peer Group Removals occurs during the Performance Period, the Company's Relative TSR Earned Percentage will be determined in accordance with Appendix A to this Exhibit B. Earned PSUs (Change in Control) If a Change in Control occurs during the Performance Period, then a number of PSUs shall become Earned PSUs based upon the Company's Relative TSR performance and TSR performance as of the date of the Change in Control, as follows: The number of PSUs that become Earned PSUs in connection with a Change in Control shall be determined by multiplying the Target Number of PSUs set forth in the Grant Notice by the Relative TSR Earned Percentage, as determined in accordance with the section "Earned PSUs (General)" above, based on the Company's actual Relative TSR and TSR attained during the Performance Period. 1

------

![](a1012026formofperformanc010.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Definitions "Aggregate Dividend" means, with respect to the Company and any Peer Group Company, the aggregate per share dividends that have an ex-dividend date during the Performance Period. "Beginning Price" means, with respect to the Company and any Peer Group Company, the Share Value as of the day immediately prior to the first day of the Performance Period. "Ending Price" means, with respect to the Company and any Peer Group Company, the Share Value as of the last day of the Performance Period. "Peer Group Companies" means only those entities set forth on Exhibit C attached hereto (the "Peer Group"); provided, however, that if a Peer Group Company is acquired or otherwise ceases to have a class of equity securities that is both registered under the Securities Exchange Act of 1934 and actively traded on a U.S. public securities market at any point during the Performance Period, such Peer Group Company will be removed from the Peer Group (such removal, a "Peer Group Removal"). Notwithstanding the foregoing, any Peer Group Companies that experience bankruptcy or become insolvent during the Performance Period will remain a part of the Peer Group and be counted as –100% for purposes of the Relative TSR determination. "Performance Period" means the period beginning on (and including) January 1, 2026 and ending on the earlier of (and including) December 31, 2028 and the date of a consummation of a Change in Control. "Relative TSR" means, with respect to the Performance Period, the Company's TSR, expressed as an ordinal ranking relative to the TSRs of each of the Peer Group Companies. "Share Value" means, with respect to the Company and any Peer Group Company, as of any given date, the twenty (20) consecutive trading-day trailing average market closing price ending on and including such date; provided, however, that if the Performance Period ends upon the consummation of a Change in Control, Share Value with respect to the Company shall mean the price per Share (or, in connection with a sale or other disposition of all or substantially all of the Company's assets, the implied price per Share, as determined by the Administrator) paid by the acquiror in connection with the Change in Control transaction or, to the extent that the consideration in the Change in Control transaction is paid in stock of the acquiror or its affiliate, then, unless otherwise determined by the Administrator, Share Value shall mean the value of the consideration paid per Share based on the average of the closing trading prices of a share of such acquiror stock on the principal exchange on which such shares are then traded for each trading day during the five consecutive trading days ending on and including the date on which a Change in Control occurs. In the event the consideration in the Change in Control takes any other form, the value of such additional consideration shall be determined by the Administrator. "TSR" means, with respect to the Company and any Peer Group Company, the quotient (expressed as a percentage carried to two decimal points) obtained by dividing (i) the sum of (A) the difference obtained by subtracting the Beginning Price from the Ending Price plus (B) the Aggregate Dividend (assuming reinvestment in the Common Stock of all dividends comprising the Aggregate Dividend as of the ex-dividend date) by (ii) the Beginning Price. 2

------

![](a1012026formofperformanc011.jpg)

Appendix A to Exhibit B PEER GROUP REMOVAL ADJUSTMENTS In the event that one Peer Group Removal occurs during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in accordance with the following table, subject to the Absolute TSR Cap: Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 175% 3 150% 4 125% 5 100% 6 85% 7 70% 8 55% 9 40% 10 35% 11 0% In the event that two Peer Group Removals occur during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in accordance with the following table, subject to the Absolute TSR Cap: Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 175% 3 150% 4 125% 5 100% 6 80% 7 60% 8 40% 9 20% 10 0% In the event that three Peer Group Removals occur during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in accordance with the following table, subject to the Absolute TSR Cap: Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 167% 3 133% 4 100% 1

------

![](a1012026formofperformanc012.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;5 85% 6 70% 7 55% 8 40% 9 0% In the event that four Peer Group Removals occur during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in accordance with the following table, subject to the Absolute TSR Cap: Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 167% 3 133% 4 100% 5 75% 6 50% 7 25% 8 0% In the event that five Peer Group Removals occur during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in accordance with the following table, subject to the Absolute TSR Cap: Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 150% 3 100% 4 80% 5 60% 6 40% 7 0% In the event that six or more Peer Group Removals occur during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in a manner determined by the Committee in its sole discretion. 2

------

![](a1012026formofperformanc013.jpg)

Exhibit C PEER GROUP COMPANIES Managed Care Healthcare IT Centene Corporation Alignment Healthcare Cigna Group HealthEquity CVS Health Corporation Hims & Hers Elevance Health Labcorp Humana Privia Health Group Molina Healthcare 1

------

## Exhibit 10.2

![](a102performancerestricte001.jpg)

Exhibit 10.2 OSCAR HEALTH, INC. 2021 INCENTIVE AWARD PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT GRANT NOTICE Oscar Health, Inc., a Delaware corporation (the "Company"), has granted to the participant listed below ("Participant") the performance-based Restricted Stock Units (the "PSUs") described in this Performance-Based Restricted Stock Unit Grant Notice (this "Grant Notice"), subject to the terms and conditions of the Oscar Health, Inc. 2021 Incentive Award Plan (as amended from time to time, the "Plan") and the Performance-Based Restricted Stock Unit Agreement attached hereto as Exhibit A, the Earned PSUs attached as Exhibit B and the Peer Group Companies attached as Exhibit C (Exhibits A, B and C, collectively, the "Agreement"), all of which are incorporated into this Grant Notice by reference. Capitalized terms not specifically defined in this Grant Notice or the Agreement have the meanings given to them in the Plan. Participant: Mark Bertolini Grant Date: March 2, 2026 Target Number of PSUs: 1,596,877 Expiration Date: December 31, 2028 Vesting Schedule: The PSUs shall become earned and vest as described in Article II of the Agreement and Exhibit B

------

![](a102performancerestricte002.jpg)

By accepting (whether in writing, electronically or otherwise) the PSUs, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. In addition, Participant acknowledges and agrees to be bound by the forfeiture provisions related to the Restrictive Covenants (as defined on Exhibit A) set forth in Section 2.1(b) of the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. OSCAR HEALTH, INC. PARTICIPANT By: /s/ Rebecca Krouse /s/ Mark Bertolini Name: Rebecca Krouse Mark Bertolini Title: Chief People Officer

------

![](a102performancerestricte003.jpg)

Exhibit A PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT WHEREAS, the Company has granted the PSUs to Participant, effective as of the Grant Date set forth in the Grant Notice (the "Grant Date"); and WHEREAS, in connection therewith, the parties desire to enter into this Performance-Based Restricted Stock Unit Agreement (together with the Grant Notice and the Vesting Schedule attached as Exhibit B hereto, this "Agreement"). NOW, THEREFORE, the Company and Participant hereby agree as follows: ARTICLE I. GENERAL I.1 Award of PSUs. Each PSU represents the right to receive one Share, as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time (if ever) the PSUs have vested. Incorporation of Terms of Plan. The PSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. Unsecured Promise. The PSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company's general assets. I.4 Definitions. Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or in the Plan. In addition, the following defined terms shall apply: (a) "Employment Agreement" means that certain Amended and Restated Employment Agreement, dated as of December 22, 2025, by and among Participant, the Company and Oscar Management Corporation, as amended from time to time. (b) "Qualifying Termination" means a termination of Participant's Service (i) by the Company without Cause, (ii) by Participant for Good Reason or (iii) due to Participant's death or Disability (each such term as defined in the Employment Agreement); provided, however, that in the event Participant experiences a termination by the Company without Cause, by Participant for Good Reason or due to Participant's death or Disability in Participant's capacity as the Chief Executive Officer of the Company and remains in Service for any duration thereafter in the capacity of a member of the Board, Participant shall be entitled to the service credit contemplated in Section 2.3(a) of this Agreement (including the 18-month additional credit), treating the date of such termination as the date Participant ceases to be a member of the Board (with settlement of such PSUs occurring on or after such date or such earlier date as is necessary to ensure the PSUs are exempt from Section 409A). (c) "Restrictive Covenants" means the restrictions set forth in Section 7 of the Employment Agreement. (d) "Service" means, notwithstanding anything to the contrary in the Plan, Participant's continued employment or service with the Company or any of its subsidiaries in Participant's capacity as the Chief Executive Officer of the Company or as a member of the Board. US-DOCS\167489195.5

------

![](a102performancerestricte004.jpg)

ARTICLE II. VESTING; FORFEITURE AND SETTLEMENT General Vesting; Forfeiture. (a) General. The PSUs will be earned as set forth on Exhibit B attached hereto. Subject to Sections 2.2 and 2.3, any Earned PSUs (as defined in Exhibit B) will vest on the Expiration Date, subject to Participant's continued Service through the Expiration Date set forth in the Grant Notice (the "Expiration Date"). Any PSUs that remain outstanding and unvested as of immediately following the Expiration Date (including as a result of failing to become Earned PSUs) automatically will be forfeited and terminated (for no consideration) as of the Expiration Date. (b) Restrictive Covenants. In consideration of the grant of the PSUs hereunder, and further as a material inducement for the Company to enter into this Agreement with Participant and to grant Participant the PSUs, Participant hereby acknowledges and agrees that Participant shall continue to be bound by the Restrictive Covenants for their express duration. In the event Participant breaches the Restrictive Covenants (as finally determined by a third-party adjudicator in accordance with the provisions of this Agreement and the Plan), then to the greatest extent permitted by Applicable Law (and except as otherwise determined by the Administrator), unvested PSUs automatically will be forfeited and terminated as of such breach without consideration therefor. Change in Control. (a) If a Change in Control occurs and Participant remains in continued Service until at least immediately prior to the Change in Control, then, effective as of the date of such Change in Control: (i) the PSUs shall become Earned PSUs in accordance with Exhibit B and (ii) (y) to the extent the Award is Assumed in connection with such Change in Control, any such Earned PSUs will convert into a time-vesting Restricted Stock Unit ("RSU") award that, following such Change in Control, will remain outstanding and eligible to vest on the Expiration Date, subject to Participant's continued Service through the Expiration Date; or (z) to the extent the Award is not Assumed in connection with such Change in Control, 100% of any such Earned PSUs will vest as of immediately prior to such Change in Control. (b) Notwithstanding the foregoing, if an Assumption occurs with respect to the Award in connection with the Change in Control, but the Successor Entity does not, in connection with such Change in Control, offer Participant employment as the Chief Executive Officer of the entity that, following the Change in Control, is the ultimate parent entity of the Company (or its successor) on terms that are no less favorable than the terms of Participant's employment with the Company immediately prior to the Change in Control (as determined by (i) the independent members of the Board and (ii) Participant), then any Earned PSUs as of the Change in Control (including any PSUs that become Earned PSUs in connection with such Change in Control) shall vest as of the date of the Change in Control. (c) Notwithstanding anything to the contrary contained in Section 8.3 of the Plan, if, following the application of Section 2.2(a), any PSUs have not become Earned PSUs as of (or in connection with) the Change in Control, then such PSUs automatically will be forfeited and terminated as of immediately prior to such Change in Control without consideration therefor. Termination of Service. (a) If Participant experiences a Qualifying Termination, then (i) the PSUs shall remain outstanding and eligible to become Earned PSUs in accordance with Exhibit B and (ii) a number US-DOCS\167489195.5

------

![](a102performancerestricte005.jpg)

of Earned PSUs shall vest in accordance with the following sentence as of the earlier of the Expiration Date or a Change in Control. The number of Earned PSUs that shall be eligible to vest shall be equal to the number of Earned PSUs determined in accordance with Exhibit B, multiplied by a fraction (which in no event shall equal more than one), (x) the numerator of which is the number of days Participant was in Service from the first day of the Performance Period through the 18-month anniversary of the Qualifying Termination and (y) the denominator of which is the number of days from (and including) the first day of the Performance Period through (and including) the Expiration Date. Any Earned PSUs that do not become vested in accordance with the foregoing automatically will be forfeited and terminated as of the last day of the Performance Period without consideration therefor. (b) Notwithstanding the foregoing or anything herein to the contrary, in the event that a Qualifying Termination occurs on or following a Change in Control (the "Post-CIC Qualifying Termination"), then all then-outstanding Earned PSUs shall vest in full as of the date of such Qualifying Termination. (c) The treatment set forth in Sections 2.3(a) and (b) above is subject to and conditioned upon Participant's (or Participant's estate's) timely execution, delivery and non-revocation of a general release of claims in the form attached to the Employment Agreement (the "Release") and on the timing contemplated by the Employment Agreement, and continued compliance with applicable Restrictive Covenants. The Company may update the Release to the extent necessary to reflect changes in law. For the avoidance of doubt, any Earned PSUs shall remain outstanding and eligible to vest following the date of any Qualifying Termination and shall actually vest upon the effective date of the Release, if later. (d) If Participant experiences a termination of Service for any reason other than due to a Qualifying Termination, all PSUs that have not become vested on or prior to the date of such termination of Service (including any Earned PSUs) automatically will be forfeited and terminated as of the termination date without consideration therefor. Settlement. (a) The PSUs (or, to the extent applicable, RSUs) will be paid in Shares as soon as administratively practicable following the applicable vesting date, but in no event later than March 15 of the year following the year in which such vesting date occurs, it being understood that the exact payment date of any PSUs (or, to the extent applicable, RSUs) shall be determined by the Company in its sole discretion (and Participant shall not have a right to designate the time of payment). (b) Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)); provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A. ARTICLE III. TAXATION AND TAX WITHHOLDING Representation. Participant represents to the Company that Participant has reviewed with Participant's own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. US-DOCS\167489195.5

------

![](a102performancerestricte006.jpg)

Tax Withholding. (a) Subject to Section 3.2(b), payment of the withholding tax obligations with respect to the Award may be by cash or check. (b) Subject to Section 10.17 of the Plan, delivery (including electronically or telephonically to the extent permitted by the Company) by Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company that Participant has placed a market sell order with such broker with respect to Shares then-issuable upon settlement of the Award, and that the broker has been directed to deliver promptly to the Company funds sufficient to satisfy the applicable tax withholding obligations; provided, that payment of such proceeds is then made to the Company at such time as may be required by the Administrator. (c) Subject to the consent of the Administrator as determined in its sole discretion which shall not be unreasonably withheld, the Company may withhold, or cause to be withheld, Shares otherwise vesting or issuable under this Award in satisfaction of any applicable withholding tax obligation. The number of Shares which may be so withheld shall be such number of Shares which have a Fair Market Value on the date of withholding equal to the aggregate amount of such liabilities based on the maximum individual statutory withholding rates in Participant's applicable jurisdictions for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such taxable income. (d) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the PSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the PSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the PSUs or the subsequent sale of Shares. The Company and its Subsidiaries do not commit and are under no obligation to structure the PSUs to reduce or eliminate Participant's tax liability. ARTICLE IV. OTHER PROVISIONS Adjustments. Participant acknowledges that the PSUs and the Shares subject to the PSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. In addition, the Relative TSR performance metrics and the Absolute TSR Cap (each, as defined in Exhibit B) are based upon, among other things, (i) certain assumptions about the future business of the Company, (ii) a management model prepared by the Company for the projected business of the Company and its Affiliates and (iii) the continued application of accounting policies used by the Company as of the Grant Date. Accordingly, in the event that, after such date, the Administrator determines that (i) any dividend or other distribution (whether in the form of cash, common stock, other securities, or other property), (ii) any unusual or nonrecurring transactions or events (including the occurrence of a regulatory event) affecting the Company or the financial statements of the Company, (iii) any changes in Applicable Laws, or (iv) any changes in generally accepted accounting principles applicable to, or the accounting policies used by, the Company occur, such that an adjustment is determined by the Administrator to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available with respect to the Award, then the Administrator shall in good faith and in such manner as it may deem equitable, adjust the applicable Relative TSR Ranking and/or Relative TSR Earned Percentage with respect to Relative TSR performance and the Absolute TSR Cap with respect to TSR performance, in any case, to reflect the effect or projected effect of such transaction(s) or event(s) on such performance levels. US-DOCS\167489195.5

------

![](a102performancerestricte007.jpg)

Clawback. Notwithstanding Section 10.13 of the Plan, the Award and the Shares issuable hereunder shall be subject to (i) any Company clawback or recoupment policy required in order to comply with Applicable Law, including the Company's Policy for Recovery of Erroneously Awarded Compensation (provided that, unless required by Applicable Law, any amendments to same shall not apply retroactively to Participant's detriment as to compensation already earned or vested prior to such amendment), and (ii) any Company clawback or recoupment policy which applies to the senior executives of the Company (provided that no such policies shall be drafted or amended such that they apply retroactively to Participant's detriment as to compensation already earned or vested prior to the effective date of such new or amended policy). The Company and Participant acknowledge that neither this Section 4.2 nor Section 10.13 of the Plan are intended to limit any clawback and/or disgorgement of the Award and/or the Shares issuable hereunder pursuant to Section 304 of the Sarbanes-Oxley Act of 2002. Notices. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company's Chief Legal Officer at the Company's principal office or the Chief Legal Officer's then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the Designated Beneficiary) at Participant's last known mailing address, email address or facsimile number in the Company's personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation. Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. Conformity to Securities Laws. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws. Successors and Assigns. The Company may assign any of its rights under this Agreement to a single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in this Agreement or the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the PSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. Entire Agreement; Amendment. The Plan, the Grant Notice and this Agreement (including any exhibit hereto and the Employment Agreement) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator or the Board; provided, however, that except as may otherwise be provided by the Plan, US-DOCS\167489195.5

------

![](a102performancerestricte008.jpg)

no amendment, modification, suspension or termination of this Agreement shall materially and adversely affect the PSUs without the prior written consent of Participant. Agreement Severable. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. Limitation on Participant's Rights. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the PSUs, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the PSUs, as and when settled pursuant to the terms of this Agreement. Not a Contract of Employment or Service. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. Counterparts. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. \* \* \* \* \* US-DOCS\167489195.5

------

![](a102performancerestricte009.jpg)

Exhibit B EARNED PSUS The number of PSUs that will become earned as of the completion of the Performance Period (such PSUs, the "Earned PSUs") shall be determined as set forth in this Exhibit B. Any Earned PSUs shall vest as set forth in Article II of the Agreement. Earned PSUs (General) The number of Earned PSUs shall be determined by multiplying the Target Number of PSUs set forth in the Grant Notice by the applicable Relative TSR Earned Percentage, as determined in accordance with the following table, provided, however, that if the Company's TSR (as defined below) for the Performance Period is less than 0%, then the Relative TSR Earned Percentage shall be equal to the lesser of 100% and the percentage determined in accordance with the table below (the "Absolute TSR Cap"): Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 175% 3 175% 4 150% 5 125% 6 100% 7 75% 8 50% 9 25% 10 25% 11 0% 12 0% In the event that the Company and one or more Peer Group Companies achieve the same TSR, then all tied companies will be deemed to have achieved the same relative TSR ranking that falls below the next higher performing Peer Group Company, if any. For example, if both the Company and a Peer Group Company achieve the same, highest TSR among the Peer Group, then both the Company and such Peer Group Company will be deemed to have earned the #1 ranking. In the event that one or more Peer Group Removals occurs during the Performance Period, the Company's Relative TSR Earned Percentage will be determined in accordance with Appendix A to this Exhibit B. Earned PSUs (Change in Control) If a Change in Control occurs during the Performance Period, then a number of PSUs shall become Earned PSUs based upon the Company's Relative TSR performance and TSR performance as of the date of the Change in Control, as follows: The number of PSUs that become Earned PSUs in connection with a Change in Control shall be determined by multiplying the Target Number of PSUs set forth in the Grant Notice by the Relative TSR Earned Percentage, as determined in accordance with the section "Earned PSUs (General)" above, based on the Company's actual Relative TSR and TSR attained during the Performance Period. US-DOCS\167489195.5

------

![](a102performancerestricte010.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Definitions "Aggregate Dividend" means, with respect to the Company and any Peer Group Company, the aggregate per share dividends that have an ex-dividend date during the Performance Period. "Beginning Price" means, with respect to the Company and any Peer Group Company, the Share Value as of the day immediately prior to the first day of the Performance Period. "Ending Price" means, with respect to the Company and any Peer Group Company, the Share Value as of the last day of the Performance Period. "Peer Group Companies" means only those entities set forth on Exhibit C attached hereto (the "Peer Group"); provided, however, that if a Peer Group Company is acquired or otherwise ceases to have a class of equity securities that is both registered under the Securities Exchange Act of 1934 and actively traded on a U.S. public securities market at any point during the Performance Period, such Peer Group Company will be removed from the Peer Group (such removal, a "Peer Group Removal"). Notwithstanding the foregoing, any Peer Group Companies that experience bankruptcy or become insolvent during the Performance Period will remain a part of the Peer Group and be counted as –100% for purposes of the Relative TSR determination. "Performance Period" means the period beginning on (and including) January 1, 2026 and ending on the earlier of (and including) December 31, 2028 and the date of a consummation of a Change in Control. "Relative TSR" means, with respect to the Performance Period, the Company's TSR, expressed as an ordinal ranking relative to the TSRs of each of the Peer Group Companies. "Share Value" means, with respect to the Company and any Peer Group Company, as of any given date, the twenty (20) consecutive trading-day trailing average market closing price ending on and including such date; provided, however, that if the Performance Period ends upon the consummation of a Change in Control, Share Value with respect to the Company shall mean the price per Share (or, in connection with a sale or other disposition of all or substantially all of the Company's assets, the implied price per Share, as determined by the Administrator) paid by the acquiror in connection with the Change in Control transaction or, to the extent that the consideration in the Change in Control transaction is paid in stock of the acquiror or its affiliate, then, unless otherwise determined by the Administrator, Share Value shall mean the value of the consideration paid per Share based on the average of the closing trading prices of a share of such acquiror stock on the principal exchange on which such shares are then traded for each trading day during the five consecutive trading days ending on and including the date on which a Change in Control occurs. In the event the consideration in the Change in Control takes any other form, the value of such additional consideration shall be determined by the Administrator. "TSR" means, with respect to the Company and any Peer Group Company, the quotient (expressed as a percentage carried to two decimal points) obtained by dividing (i) the sum of (A) the difference obtained by subtracting the Beginning Price from the Ending Price plus (B) the Aggregate Dividend (assuming reinvestment in the Common Stock of all dividends comprising the Aggregate Dividend as of the ex-dividend date) by (ii) the Beginning Price. US-DOCS\167489195.5

------

![](a102performancerestricte011.jpg)

Appendix A to Exhibit B PEER GROUP REMOVAL ADJUSTMENTS In the event that one Peer Group Removal occurs during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in accordance with the following table, subject to the Absolute TSR Cap: Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 175% 3 150% 4 125% 5 100% 6 85% 7 70% 8 55% 9 40% 10 35% 11 0% In the event that two Peer Group Removals occur during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in accordance with the following table, subject to the Absolute TSR Cap: Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 175% 3 150% 4 125% 5 100% 6 80% 7 60% 8 40% 9 20% 10 0% In the event that three Peer Group Removals occur during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in accordance with the following table, subject to the Absolute TSR Cap: Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 167% 3 133% 4 100% US-DOCS\167489195.5

------

![](a102performancerestricte012.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;5 85% 6 70% 7 55% 8 40% 9 0% In the event that four Peer Group Removals occur during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in accordance with the following table, subject to the Absolute TSR Cap: Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 167% 3 133% 4 100% 5 75% 6 50% 7 25% 8 0% In the event that five Peer Group Removals occur during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in accordance with the following table, subject to the Absolute TSR Cap: Relative TSR Ranking Relative TSR Earned Percentage 1 200% 2 150% 3 100% 4 80% 5 60% 6 40% 7 0% In the event that six or more Peer Group Removals occur during the Performance Period, the Company's Relative TSR performance achieved during the Performance Period will be determined in a manner determined by the Committee in its sole discretion. US-DOCS\167489195.5

------

![](a102performancerestricte013.jpg)

Exhibit C PEER GROUP COMPANIES Managed Care Healthcare IT Centene Corporation Alignment Healthcare Cigna Group HealthEquity CVS Health Corporation Hims & Hers Elevance Health Labcorp Humana Privia Health Group Molina Healthcare

------

## Exhibit 10.3

![](a103restrictedstockunita001.jpg)

Exhibit 10.3 OSCAR HEALTH, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Oscar Health, Inc., a Delaware corporation (the "Company"), has granted to the participant listed below ("Participant") the Restricted Stock Units (the "RSUs") described in this Restricted Stock Unit Grant Notice (this "Grant Notice"), subject to the terms and conditions of the Oscar Health, Inc. 2021 Incentive Award Plan (as amended from time to time, the "Plan") and the Restricted Stock Unit Agreement attached hereto as Exhibit A (the "Agreement"), both of which are incorporated into this Grant Notice by reference. Capitalized terms not specifically defined in this Grant Notice or the Agreement have the meanings given to them in the Plan. Participant: Mark Bertolini Grant Date: March 2, 2026 Number of RSUs: 1,596,877 Vesting Commencement Date: March 1, 2026 Vesting Schedule: The RSUs shall vest with respect to 1/3 of the RSUs granted hereunder on each of the first three anniversaries of the Vesting Commencement Date, subject to Participant's continued Service (as defined on Exhibit A) through the applicable vesting date (except as provided in the Agreement).

------

![](a103restrictedstockunita002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;By accepting (whether in writing, electronically or otherwise) the RSUs, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. In addition, Participant acknowledges and agrees to be bound by the forfeiture provisions related to the Restrictive Covenants (as defined on Exhibit A) set forth in Section 2.1(b) of the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. OSCAR HEALTH, INC. PARTICIPANT By: /s/ Rebecca Krouse /s/ Mark Bertolini Name: Rebecca Krouse Mark Bertolini Title: Chief People Officer

------

![](a103restrictedstockunita003.jpg)

Exhibit A RESTRICTED STOCK UNIT AGREEMENT ARTICLE I. GENERAL (a) Award of RSUs. The Company has granted the RSUs to Participant effective as of the Grant Date set forth in the Grant Notice (the "Grant Date"). Each RSU represents the right to receive one Share as set forth in this Restricted Stock Unit Agreement (this "Agreement"). Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested. Incorporation of Terms of Plan. The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. Unsecured Promise. The RSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company's general assets. I.4 Definitions. Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan. In addition, the following defined terms shall apply: (a) "Employment Agreement" means that certain Amended and Restated Employment Agreement, dated as of December 22, 2025, by and among Participant, the Company and Oscar Management Corporation, as amended from time to time. (b) "Qualifying Termination" means a termination of Participant's Service (i) by the Company without Cause, (ii) by Participant for Good Reason or (iii) due to Participant's death or Disability (each such term as defined in the Employment Agreement); provided, however, that in the event Participant experiences a termination by the Company without Cause, by Participant for Good Reason or due to Participant's death or Disability in Participant's capacity as the Chief Executive Officer of the Company and remains in Service for any duration thereafter in the capacity of a member of the Board, Participant shall be entitled to the service credit contemplated in Section 2.1(d)(i) of this Agreement (including the 18-month additional credit), treating the date of such termination as the date Participant ceases to be a member of the Board (with settlement of such RSUs occurring on or after such date or such earlier date as is necessary to ensure the RSUs are exempt from Section 409A (it being understood that in any such vesting and settlement during Participant's Service as a member of the Board that may be necessary for tax purposes shall be without prejudice to Participant's continued vesting in the remaining RSUs in connection with such ongoing Service)). (c) "Restrictive Covenants" means the restrictions set forth in Section 7 of the Employment Agreement, as well as any other restrictive covenants to which Participant is bound pursuant to any written agreement with the Company or any of its Subsidiaries. (d) "Service" means, notwithstanding anything to the contrary in the Plan, Participant's continued employment or service with the Company or any of its subsidiaries in Participant's capacity as the Chief Executive Officer of the Company or as a member of the Board. ARTICLE II. VESTING; FORFEITURE AND SETTLEMENT Vesting; Forfeiture; Change in Control; Termination of Service. 1

------

![](a103restrictedstockunita004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;(a) General. Subject to Sections 2.1(b), (c) and (d) below, the RSUs will vest according to the vesting schedule in the Grant Notice, except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. (b) Restrictive Covenants. In consideration of the grant of the RSUs hereunder, and further as a material inducement for the Company to enter into this Agreement with Participant and to grant Participant the RSUs, Participant hereby acknowledges and agrees that Participant shall continue to be bound by the Restrictive Covenants. In the event Participant breaches the Restrictive Covenants (as finally determined by a third-party adjudicator in accordance with the provisions of this Agreement and the Plan), then to the greatest extent permitted by Applicable Law (and except as otherwise determined by the Administrator), unvested RSUs automatically will be forfeited and terminated as of such breach without consideration therefor. (c) Change in Control. Notwithstanding the generality of Section 2.1(a) above, (i) if an Assumption does not occur with respect to the Award in connection with the Change in Control, any RSUs as of the Change in Control shall vest as of the date of the Change in Control in accordance with Section 8.3 of the Plan and (ii) if an Assumption occurs with respect to the Award in connection with the Change in Control, but the Successor Entity does not, in connection with such Change in Control, offer Participant employment as the Chief Executive Officer of the entity that, following the Change in Control, is the ultimate parent entity of the Company (or its successor) on terms that are no less favorable than the terms of Participant's employment with the Company immediately prior to the Change in Control (as determined by (i) the independent members of the Board and (ii) Participant), then any RSUs as of the Change in Control shall vest as of the date of the Change in Control. (d) Qualifying Termination. (i) If Participant experiences a Qualifying Termination, then the RSUs shall vest on an accelerated basis as of the date of such Qualifying Termination in an amount equal to the number of RSUs that would have vested had Participant remained in continuous Service until the 18-month anniversary of the Qualifying Termination, and assuming the RSUs vest in equal daily installments (rather than annual installments) over the vesting period. Notwithstanding the foregoing, in the event that a Qualifying Termination (including if Participant ceases to serve as a member of the Board at the request or as a result of the actions of the Company, its affiliates, an acquirer or other third party) occurs on or following a Change in Control, then all RSUs hereunder shall (to the extent then-unvested) become fully vested on an accelerated basis as of the date of such Qualifying Termination. (ii) The treatment set forth in Section 2.1(d)(i) is subject to and conditioned upon Participant's (or Participant's estate's) timely execution, delivery and non-revocation of a general release of claims substantially in the form attached to the Employment Agreement (the "Release") and on the timing contemplated by the Employment Agreement, and continued compliance with applicable Restrictive Covenants. The Company may update the Release to the extent necessary to reflect changes in law. For the avoidance of doubt, any unvested RSUs as of the date of any Qualifying Termination shall remain outstanding and eligible to vest following the date of any Qualifying Termination and shall actually vest upon the effective date of the Release, if later. (e) Other Terminations of Service. In the event of a termination of Participant's Service for any reason other than due to a Qualifying Termination, all then-unvested RSUs will immediately and automatically be cancelled and forfeited as of the date of such termination without consideration therefor, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company. 2

------

![](a103restrictedstockunita005.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Settlement. (a) The RSUs will be paid in Shares as soon as administratively practicable after the vesting of the applicable RSU, but in no event later than 30 days following the RSU's vesting date, it being understood that the exact payment date of any RSUs shall be determined by the Company in its sole discretion (and Participant shall not have a right to designate the time of payment). (b) Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)); provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A. ARTICLE III. TAXATION AND TAX WITHHOLDING Representation. Participant represents to the Company that Participant has reviewed with Participant's own tax advisors the tax consequences of this award of RSUs (the "Award") and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. Tax Withholding. (a) Subject to Section 3.2(b), payment of the withholding tax obligations with respect to the Award may be by cash or check. (b) Subject to Section 10.17 of the Plan, delivery (including electronically or telephonically to the extent permitted by the Company) by Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company that Participant has placed a market sell order with such broker with respect to Shares then-issuable upon settlement of the Award, and that the broker has been directed to deliver promptly to the Company funds sufficient to satisfy the applicable tax withholding obligations; provided, that payment of such proceeds is then made to the Company at such time as may be required by the Administrator. (c) Subject to the consent of the Administrator as determined in its sole discretion which shall not be unreasonably withheld, the Company may withhold, or cause to be withheld, Shares otherwise vesting or issuable under this Award in satisfaction of any applicable withholding tax obligation. The number of Shares which may be so withheld shall be such number of Shares which have a Fair Market Value on the date of withholding equal to the aggregate amount of such liabilities based on the maximum individual statutory withholding rates in Participant's applicable jurisdictions for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such taxable income. (d) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the RSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the RSUs or the subsequent sale of Shares. The Company and its Subsidiaries do not commit and are under no obligation to structure the RSUs to reduce or eliminate Participant's tax liability. 3

------

![](a103restrictedstockunita006.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;ARTICLE IV. OTHER PROVISIONS Adjustments. Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. IV.2 Clawback. Notwithstanding Section 10.13 of the Plan, the Award and the Shares issuable hereunder shall be subject to (i) any Company clawback or recoupment policy required in order to comply with Applicable Law, including the Company's Policy for Recovery of Erroneously Awarded Compensation (provided that, unless required by Applicable Law, any amendments to same shall not apply retroactively to Participant's detriment as to compensation already earned or vested prior to such amendment), and (ii) any Company clawback or recoupment policy approved by the Board which applies to the senior executives of the Company (provided that no such policies shall be drafted or amended such that they apply retroactively to Participant's detriment as to compensation already earned or vested prior to the effective date of such new or amended policy). The Company and Participant acknowledge that neither this Section 4.2 nor Section 10.13 of the Plan are intended to limit any clawback and/or disgorgement of the Award and/or the Shares issuable hereunder pursuant to Section 304 of the Sarbanes-Oxley Act of 2002. Notices. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company's Chief Legal Officer at the Company's principal office or the Chief Legal Officer's then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the Designated Beneficiary) at Participant's last known mailing address, email address or facsimile number in the Company's personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation. Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. Conformity to Securities Laws. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws. Successors and Assigns. The Company may assign any of its rights under this Agreement to a single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in this Agreement or the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. 4

------

![](a103restrictedstockunita007.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement; Amendment. The Plan, the Grant Notice, this Agreement (including any exhibit hereto) and the Employment Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator or the Board; provided, however, that except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall materially and adversely affect the RSUs without the prior written consent of Participant. Agreement Severable. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. Limitation on Participant's Rights. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the RSUs, as and when settled pursuant to the terms of this Agreement. Not a Contract of Employment or Service. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. Counterparts. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. \* \* \* \* \* 5

------

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION**

I, Mark T. Bertolini, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Oscar Health, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: **May 7, 2026** | By: | /s/ Mark T. Bertolini |
|  |  | **Mark T. Bertolini** |
|  |  | **Chief Executive Officer** |
|  |  | *(Principal Executive Officer)* |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION**

I, R. Scott Blackley, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Oscar Health, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: **May 7, 2026** | By: | /s/ R. Scott Blackley |
|  |  | **R. Scott Blackley** |
|  |  | **Chief Financial Officer** |
|  |  | *(Principal Financial Officer)* |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Oscar Health, Inc. (the "Company") for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: **May 7, 2026** | By: | /s/ Mark T. Bertolini |
|  |  | **Mark T. Bertolini** |
|  |  | **Chief Executive Officer** |
|  |  | *(Principal Executive Officer)* |

---

## Exhibit 32.2

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Oscar Health, Inc. (the "Company") for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: **May 7, 2026** | By: | /s/ R. Scott Blackley |
|  |  | **R. Scott Blackley** |
|  |  | **Chief Financial Officer** |
|  |  | *(Principal Financial Officer)* |

---

<br>